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Abstract 
People with type 1 and type 2 diabetes are at risk of developing progressive chronic kidney disease (CKD) and end‑
stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albu‑
minuria, impaired kidney function, end‑stage kidney disease and cardiovascular disease. Blood pressure control has 
been shown to be beneficial in people with diabetes in slowing progression of kidney disease and reducing cardio‑
vascular events. However, randomised controlled trial evidence differs in type 1 and type 2 diabetes and different 
stages of CKD in terms of target blood pressure. Activation of the renin‑angiotensin‑aldosterone system (RAAS) is an 
important mechanism for the development and progression of CKD and cardiovascular disease. Randomised trials 
demonstrate that RAAS blockade is effective in preventing/ slowing progression of CKD and reducing cardiovascular 
events in people with type 1 and type 2 diabetes, albeit differently according to the stage of CKD. Emerging therapy 
with sodium glucose cotransporter‑2 (SGLT‑2) inhibitors, non‑steroidal selective mineralocorticoid antagonists and 
endothelin‑A receptor antagonists have been shown in randomised trials to lower blood pressure and further reduce 
the risk of progression of CKD and cardiovascular disease in people with type 2 diabetes. This guideline reviews the 
current evidence and makes recommendations about blood pressure control and the use of RAAS‑blocking agents in 
different stages of CKD in people with both type 1 and type 2 diabetes.
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Introduction
A significant percentage of people with diabetes 
develop chronic kidney disease (CKD), and diabetes 
is also a leading cause of end-stage kidney disease [1]. 
Nearly a third of people who are on dialysis in the UK 
have diabetes [2]. Diabetic kidney disease (DKD), an 
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umbrella term used to describe diabetic nephropathy 
and CKD in diabetes, is associated with high morbidity 
and mortality, predominantly related to cardiovascular 
complications, and the progression to kidney failure 
requiring renal replacement therapy. Hypertension is a 
modifiable risk factor for cardiovascular complications 
and progression of CKD [3].
Angiotensin converting enzyme inhibitors (ACEi) and 
angiotensin receptor II blockers (ARB) are established 
treatment to slow the progression of DKD and reduce 
cardiovascular events. Novel agents such as sodium glu-
cose cotransporter-2 (SGLT-2) inhibitors, non-steroidal 
selective mineralocorticoid receptor antagonists and 
endothelin A receptor antagonists have recently been 
demonstrated to improve clinical outcomes and lower 
blood pressure, and are likely to be used in the routine 
management of DKD in the future [4].
The scope of this update includes lifestyle advice, blood 
pressure targets and antihypertensive therapies in differ-
ent categories of patients with DKD. Accurate measure-
ment of blood pressure is vitally important before starting 
and during monitoring of antihypertensive treatment. 
Separate recommendation for blood pressure measure-
ment has not been made in this guidance. We suggest the 
British and Irish Hypertension Society’s (BIHS) guidance 
on standardised, automated blood pressure measurement 
is followed. The blood pressure thresholds and targets in 
this guideline refer to standardised office blood pressure 
readings unless specified otherwise.
This guidance is for a variety of clinicians who treat 
people with diabetic kidney disease, including primary 
care physicians and specialists in diabetes, cardiology 
and nephrology. It intends to harmonise practices of 
blood pressure monitoring, and pharmacological and 
non-pharmacological management of hypertension, 
which vary considerably in different settings.
The guideline provides separate recommendations for 
type 1 and type 2 diabetes, with type 2 further divided 
into early (CKD stages 1–3) as well as advanced CKD 
(CKD stages 4–5), and dialysis patients (see Table  1, 
Fig.  1). The diagnosis and management of post solid 
organ transplantation diabetes have been discussed in a 
separate guidance. The main research recommendations 
appear as a separate section and the audit standards are 
included in the supplementary file.
Hypertension management 
and renin‑angiotensin‑aldosterone system blockade 
in people with type 1 diabetes with CKD stages 1–5 non 
dialysis
Recommendations (Table 2)
Despite improvements in prognosis, diabetic nephrop-
athy in people with type 1 diabetes remains a major 
cause of end-stage renal disease [5]. The onset of micro- 
and macroalbuminuria in people with type 1 diabe-
tes heralds not only an increased risk of renal disease, 
but also an increased risk of cardiovascular disease [6]. 
Early prospective studies suggested that around 30–50% 
of people with type 1 diabetes will develop microal-
buminuria, in whom a 6% increase in risk of coronary 
heart disease is seen per 5 mg increase in 24-h albu-
min excretion rate (AER) [6]. The natural history of 
diabetic nephropathy in people with type 1 diabetes 
has, however, changed over the past 4 decades. Stud-
ies in the 1970s and 1980s suggested that progression 
to end-stage kidney disease in people with macroalbu-
minuria would occur within 7 years [7]. More recent 
follow-up data of significant numbers of people with 
Table 1 Blood pressure targets in people with diabetes through stages of kidney function impairment
CKD chronic kidney disease, BP blood pressure
a For adults > 65 years a higher target > 140/90 may be appropriate
b For frail adults > 75 years a higher target > 150/90 may be appropriate to avoid side effects
c Monitor and target inter-dialytic home BP for people on dialysis
d  Lower targets for younger adults aged < 30
Stage of kidney function impairment





CKD stages 1–3 CKD stages 4–5 (non‑
dialysis)
CKD stage 5 (dialysis)
Type 1 diabe‑












≤140/90 (2D)c (interdialytic 
BP)
Type 2 diabe‑




< 150/90 (2B)b (for 
≥75 years)
< 130/80 (2D) < 130/80 (2D) < 140/90 (1B)a
< 130/80 for albuminuric 
(2C)
< 140/90 (2D)c (interdialytic 
BP)
Page 3 of 31Banerjee et al. BMC Nephrology            (2022) 23:9  
type 1 diabetes suggest that end-stage kidney disease 
occurs in around 3% of people who have had diabetes 
for 10 years [8] and in around 8% of people who have 
had diabetes for 30 years [9].
There is a significant body of evidence to suggest that 
over-activation of the RAAS plays a major role in the 
pathogenesis of diabetic nephropathy in people with type 
1 diabetes [10]. Over-activation of the RAAS is observed 
in people with type 1 diabetes, even in the absence of dia-
betic nephropathy [11]. Angiotensin II-mediated increase 
in intraglomerular pressure appears to be an important 
mechanism by which renal disease progresses in peo-
ple with type 1 diabetes who have diabetic nephropathy 
[12, 13], and reductions in intraglomerular pressure may 
ameliorate glomerular injury. Angiotensin II also has 
mitogenic effects that may lead to mesangial expansion 
that is characteristic of diabetic nephropathy [14]. Over-
activation of the RAAS may be mediated by hypergly-
caemia [15], and blockade of the RAAS may in turn be 
impaired by hyperglycaemia [13]. RAAS over-activation 
is also described in people with type 1 diabetes who have 
glomerular hyperfiltration [16].
Hypertension in people with type 1 diabetes
Risk factors for the development of nephropathy in peo-
ple with type 1 diabetes include increasing age, duration 
of diabetes, male gender and hyperglycaemia [17]. The 
possible role of genetic factors has long been hypoth-
esised, due to the observation that a family history of 
hypertension appears to predict the development of 
nephropathy [18]. It has been suggested that a family his-
tory of hypertension could be the basis for more intensive 
antihypertensive therapy in people with type 1 diabetes.
The risk factor that has the strongest association with 
progression of diabetic nephropathy is hypertension. 
Prospective evaluation of 148 people with type 1 dia-
betes who were normoalbuminuric showed that those 
who developed microalbuminuria had a significantly 
higher baseline blood pressure compared with those 
who remained normoalbuminuric (138/82 mmHg versus 
123/73 mmHg) [19]. Similarly, follow-up of a Scandina-
vian cohort of over 300 children and adolescents with 
type 1 diabetes showed that systolic blood pressure was a 
major risk factor for the development of microalbuminu-
ria over 5 years [20]. Analysis of 1441 people with type 1 
Fig. 1 Steps in the management of hypertension in people with diabetes and CKD
Table 2 Recommendations for people with type 1 diabetes
a We suggest a target upright blood pressure in younger adults of 120/80 mmHg and 140/90 mmHg for those aged over 65 (Grade 2D)
b Between the ages of 30–65 for some people with higher life-time risk through earlier age of onset of type 1 diabetes, it may be appropriate to target a diastolic BP of 
< 80 mmHg (Grade 2C)
Recommendations for renin‑angiotensin‑aldosterone system (RAAS) blockade and hypertension management in people with type 1 
diabetes
    1. a. In people with type 1 diabetes and urine albumin:creatinine ratio (UACR) < 3 mg/mmol [< 26.55 mg/g]), we recommend a threshold for blood 
pressure therapy of a persistent upright (sitting or standing) blood pressure that is ≥140/90 mmHg (1B)a, b.
b. In children and adolescents with type 1 diabetes, hypertension is defined as average systolic blood pressure and/or diastolic blood pressure that is 
greater than the 95th percentile for the person’s gender, age and height on more than three occasions (Grade 1B).
    2. We recommend that angiotensin‑converting‑enzyme inhibitor (ACEI) therapy should be used as a first‑line agent for blood pressure lowering 
and, if ACEI therapy is contraindicated or not tolerated, angiotensin receptor blockers (ARBs) should be considered (Grade 1B).
    3. In most adults with type 1 diabetes and persistent UACR > 3 mg/mmol (> 26.55 mg/g), we recommend that ACEI therapy should be considered 
irrespective of blood pressure, and that the target upright blood pressure should be ≤130/80 mmHg (1B) if higher pre‑treatment in younger adults 
but ≤140/90 mmHg for those aged over 65 (2D). We recommend that the dose of ACEI should be titrated to the maximum tolerated (Grade 1B).
    4. There is no current evidence to support a role for ACEI therapy for blood pressure control or renal protection in people with type 1 diabetes who 
are normotensive and have UACR < 3 mg/mmol[< 26.55 mg/g]) (Grade 1C).
    5. There is some evidence to support the use of candesartan to prevent the development or progression of retinopathy in people with type 1 
diabetes who are normotensive and have UACR < 3 mg/mmol [< 26.55 mg/g]) (Grade 1C).
    6. There is no firm evidence to support a role of dual blockade of the RAAS in people with type 1 diabetes (Grade 1C).
    7. We recommend that people with type 1 diabetes should be advised to stop RAAS‑blocking drugs during periods of acute illness and restart on 
recovery (Grade 1C).
    8. We recommend that women of childbearing age should be encouraged to stop RAAS‑blocking drugs prior to actively considering pregnancy 
(Grade 1B).
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diabetes in the Diabetes Control and Complications Trial 
(DCCT) cohorts suggests that systolic blood pressure 
levels below 120 mmHg are associated with a 41% reduc-
tion in macroalbuminuria (95% confidence interval [CI] 5 
to 63%) and a 68% reduction in CKD stage 3 (95% CI 25 
to 84%) [21]. The Pittsburgh EDC study 25-year follow-
up results support an optimal blood pressure of 120/80 in 
childhood onset type 1 diabetes [22].
The threshold for diagnosis of hypertension in people 
with type 1 diabetes varies according to national and 
international guidelines. The Kidney Disease Improving 
Global Outcomes (KDIGO) guidelines suggest a blood 
pressure goal of ≤140/90 mmHg if urinary AER is under 
30 mg per 24 h, or ≤ 130/80 mmHg if AER exceeds 30 mg 
per 24 h, although they do not distinguish between type 
1 and type 2 diabetes [23]. National Institute for Health 
and Care Excellence (NICE) guidelines on the manage-
ment of people with type 1 diabetes suggest a blood 
pressure target of 130/80 mmHg in someone with albu-
minuria (135/85 mmHg in those who were normoalbu-
minuric) [24]. The American Diabetes Association and 
American Society of Nephrology consensus guidelines 
suggest that a blood pressure of < 140/90 mmHg should 
be attained in all individuals with diabetes and renal 
disease, but they do not suggest a lower target and they 
do not distinguish between type 1 and type 2 diabetes 
[25]. In children with type 1 diabetes, the International 
Society for Pediatric and Adolescent Diabetes (ISPAD) 
defines hypertension as average systolic blood pressure 
and/or diastolic blood pressure that is greater than the 
95th percentile for the person’s gender, age and height 
on more than three occasions, and suggests a target 
blood pressure of 130/80 mmHg [26]. Given the younger 
age of many adults with type 1 diabetes and the conse-
quent longer lifetime blood pressure burden, we support 
the targets of 120–140/80 mmHg according to age and 
the presence or absence of albuminuria, with those aged 
over 65 being better suited to the 140/90 mmHg target 
[27–29].
The role of home and ambulatory blood pressure meas-
urement in the diagnosis and management of hyperten-
sion in people with type 1 diabetes and nephropathy is 
unclear. Small cohort studies of children and adults with 
type 1 diabetes suggest that an increase in nocturnal sys-
tolic blood pressure or blunting of nocturnal dipping is 
an important factor in progression to microalbuminuria 
in people with type 1 diabetes [30, 31]. Due to a lack of 
robust evidence, no guidelines currently recommend 
ambulatory or home blood pressure monitoring to diag-
nose or manage hypertension in people with type 1 dia-
betes, although the ISPAD guidelines suggest that there 
may be a role for 24-h blood pressure monitoring in the 
diagnosis of hypertension in children [26].
The importance of lifestyle measures (weight loss and 
salt intake reduction) are highlighted by a number of 
guidelines, and indeed a recent study suggests that lower 
sodium intake may improve the efficacy of RAAS block-
ade [32].
There is evidence to suggest that management of blood 
pressure in people with type 1 diabetes may be subop-
timal. In a large cross-sectional study of people with 
type 1 diabetes in Scandinavia, those on antihyperten-
sive therapy who were achieving a blood pressure below 
130/80 mmHg varied according to degree of albuminu-
ria [33]. Blood pressure above 130/80 mmHg was seen 
in 74.6% of people who were normoalbuminuric; 71.2% 
of people who were microalbuminuric; 80.0% of peo-
ple who were macroalbuminuric; 88.1% of people who 
were treated with dialysis; and 90.4% of people who had 
received a renal transplant.
An important point to consider is the presence of pos-
tural hypotension in people with type 1 diabetes. Auto-
nomic neuropathy is often associated with postural 
hypotension, and people with type 1 diabetes should have 
their supine and standing blood pressure checked. A sig-
nificant drop in blood pressure on standing (> 20 mmHg) 
might alert the clinician to ensure that care is taken not 
to treat the person’s blood pressure over-aggressively. 
Otherwise we advocate the use of upright (sitting or 
standing) blood pressure as the target blood pressure, as 
per British Hypertension Society guidelines [34].
Modulation of the RAAS in people with type 1 diabetes
Normoalbuminuria There has been some interest in the 
use of agents that block the RAAS in the primary preven-
tion of diabetic renal disease. The use of ACEIs has been 
tested in people who are normotensive and normoalbu-
minuric, and there is little evidence of a protective effect 
on the development of diabetic nephropathy. Impor-
tantly, however, many of these studies have used defini-
tions of blood pressure that would now be considered to 
be too high. A multicentre European study examined 530 
people with type 1 diabetes and blood pressure under 
155/90 mmHg [35]. The study found that during 2 years 
of treatment with lisinopril versus placebo, the ACEI 
showed no protective effect against the development of 
microalbuminuria. Similar findings have been shown 
with candesartan [36]. Furthermore, a renal biopsy 
study of 285 people with type 1 diabetes who were nor-
motensive and normoalbuminuric showed no effect of 
enalapril or losartan in the development of renal lesions 
[37]. One short study did suggest a significant reduction 
in urine albumin:creatinine ratio (UACR) in 89 individu-
als with type 1 diabetes who were normotensive and 
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normoalbuminuric and who were treated with placebo or 
perindopril for 4 months [38]. Currently however, the use 
of ACE inhibition in people with type 1 diabetes who are 
normotensive and normoalbuminuric cannot be recom-
mended on the basis of trial evidence.
Microalbuminuria The onset of microalbuminuria 
in someone with type 1 diabetes was once thought to 
lead to inevitable progression to macroalbuminuria and 
thence to progressive kidney disease [39]. More recently, 
however, it has become clearer that microalbuminuria 
may remit in up to 40% of people with type 1 diabetes 
[40–42]. In addition, microalbuminuria may not progress 
to macroalbuminuria in a significant number of people 
[43]. In the Renin-Angiotensin System Study, onset of 
microalbuminuria correlated poorly with renal biopsy 
findings of diabetic glomerulopathy [44]. Previous studies 
have also described progressive renal impairment with-
out microalbuminuria in people with type 1 diabetes [44, 
45].
In adolescents with type 1 diabetes, modest but persis-
tent elevations of UACR in the normal range may be 
associated with progression to persistent microalbumi-
nuria [46]. Furthermore, a persistently raised UACR at 
the upper limit of the reference range in adolescents is 
associated with increasing aortic intima-media thicken-
ing, which is a sensitive marker of early atherosclerosis 
[47].
It is, however, recognised that the presence of microal-
buminuria may not be the ideal risk marker for progres-
sive renal dysfunction in people with type 1 diabetes [48]. 
Microalbuminuria may progress, stabilise or regress, and 
factors that govern this change are unclear, especially in 
adolescents and young adults who have improved glycae-
mia control [41]. Therefore, more reliable biomarkers or 
genetic markers are needed to predict which individuals 
are at the greatest risk of progressive renal disease. Many 
studies have looked at putative genetic loci within the 
RAAS for a genetic predisposition to diabetic nephrop-
athy, but no clear correlation with nephropathy risk has 
been found in most studies [49]. Some authorities sug-
gest that determination of serum cystatin C in people 
with diabetes and proteinuria may provide better risk 
stratification of subsequent end-stage kidney disease 
than determination of serum creatinine [50]. Serum con-
centration of tumour necrosis factor (TNF) receptors 1 
or 2 (TNFR1, TNFR2) may also be predictors of future 
development of CKD stage 3 in people with type 1 dia-
betes [51]. If those who are at high risk of progression 
to diabetic nephropathy could be identified early, more 
intensive systematic therapy could be considered, for 
example closed loop insulin delivery system or pancreas 
transplantation [52].
There are few long-term studies that suggest that treat-
ing people with type 1 diabetes, microalbuminuria and 
normal blood pressure reduces end-stage kidney dis-
ease. There are, however, more short-term studies that 
focus on a change in AER rather than a change in renal 
function. A multicentre European study examined 79 
individuals with microalbuminuria and blood pressure 
below 155/90 mmHg, and found a significant reduction 
in AER in the group of people who were treated with 
lisinopril compared with those who were treated with 
a placebo (− 34.2 mg/min) [17]. In an 8-year follow-up 
of a small number of people with type 1 diabetes and 
microalbuminuria, 10% of people who were treated 
with captopril progressed to macroalbuminuria, com-
pared with 40% of those who were treated with a placebo 
[53]; therefore, treatment with captopril was associated 
with a reduction in progression of renal disease. Simi-
larly, the Microalbuminuria Collaborative Study Group 
treated 235 people with microalbuminuria and blood 
pressure < 160/90 mmHg with placebo or captopril [54]. 
Progression to macroalbuminuria was seen in 21.9% of 
the placebo-treated group compared with 7.2% of the 
captopril-treated group (the risk reduction was 69%). 
The Ace-Inhibitor Trial to Lower Albuminuria in Nor-
motensive Insulin-Dependent Subjects (ATLANTIS) 
study used ramipril versus placebo in 140 people with 
type 1 diabetes and microalbuminuria and normoten-
sion, and it showed regression to normoalbuminuria in 
20% of the ramipril-treated group, compared with 4% 
of the placebo-treated group [55]. A further study of 20 
individuals with type 1 diabetes, microalbuminuria and 
normal blood pressure who were treated with placebo or 
enalapril showed a reduction in progression to macroal-
buminuria and a significant number of people regressed 
to normoalbuminuria [56].
RAAS blockade may have positive longer-term impacts 
on renal haemodynamics in people with type 1 diabetes 
even when therapy is stopped. In the 5-year Renin-Angi-
otensin System Study, people who were on RAAS block-
ade during the trial, but who stopped therapy after the 
trial, showed significantly greater renal haemodynamic 
responses to clamped hyperglycaemia and flow-mediated 
vasodilatation, which suggests that RAAS blockade has 
sustained, long-term protective effects [37].
In people who are hypertensive and have microalbu-
minuria, however, there is relatively strong evidence to 
suggest that ACE inhibition slows progression of dia-
betic nephropathy in people with type 1 diabetes and 
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microalbuminuria [57]. Meta-analysis suggests that 
ACEIs reduce progression of microalbuminuria to mac-
roalbuminuria (odds ratio 0.38; 95% CI 0.25 to 0.57) [58]. 
Outcomes in terms of the prevention of end-stage kidney 
disease, however, have not been reported.
Macroalbuminuria For decades, the presence of mac-
roalbuminuria in people with type 1 diabetes has been 
considered to be a stage of irreversible kidney disease. 
However, recent long-term follow-up of 159 individuals 
with type 1 diabetes in the Diabetes Control and Com-
plications Trial / Epidemiology of Diabetes Interventions 
and Complications (DCCT/EDIC) study showed that 
10 years after onset of macroalbuminuria, the cumula-
tive incidence of reduction to microalbuminuria was 52% 
[43]. The cumulative incidence of CKD stage 3 (estimated 
glomerular filtration rate (eGFR) < 60 mL/min/1.73  m2) 
was 32%, and the cumulative incidence of end-stage kid-
ney disease was 16% after 10 years, with better glucose 
and blood pressure control being the main factors asso-
ciated with a lower risk of CKD progression. Therefore, 
while macroalbuminuria appears to be an important 
renal disease risk marker, it is far from inevitable that 
relentless progression to end-stage kidney disease will 
occur.
Seminal studies in the 1980s suggested that early 
aggressive antihypertensive therapy could reduce the 
rate of decline of renal function in people with diabetic 
nephropathy [59], and further studies of people with 
type 1 diabetes, hypertension and macroalbuminuria 
demonstrated the specific protective effects of ACEI 
drugs on progression of albuminuria and renal disease 
[60–62]. Meta-analysis of these studies suggest a long-
term beneficial effect on preventing doubling of serum 
creatinine and development of end-stage kidney dis-
ease [63].
Use of other agents that modulate the RAAS Candesar-
tan has been studied in people with type 1 diabetes and 
diabetic retinopathy [64]. A beneficial effect of candesar-
tan was seen in the protection of retinopathy; although in 
one study, the benefit of RAAS blockade was limited to 
people with poor glucose control (glycated haemoglobin 
(haemoglobin A1c) > 7.5%) [15, 64]. Studies using ARBs 
have not been widely reported in type 1 diabetes and 
nephropathy. In a small Danish study, losartan was seen 
to attenuate AER in people with type 1 diabetes [65]. In 
the Renin-Angiotensin System Study, however [37], use 
of losartan did not appear to protect people from devel-
oping microalbuminuria: indeed 17% of people on losar-
tan developed microalbuminuria compared with 6% on a 
placebo and 4% on enalapril over 5 years.
It has been suggested that aldosterone escape dur-
ing long-term RAAS blockade may be a mechanism by 
which ACE inhibition fails to prevent progressive renal 
disease in people with type 1 diabetes [66]. Thus, the use 
of aldosterone antagonists in such individuals may be 
useful. Spironolactone has been investigated in a small 
study of people with type 1 diabetes and microalbuminu-
ria [67]. Spironolactone added to standard antihyperten-
sive therapy reduced AER by 60%, with no drop in blood 
pressure and a minor drop in eGFR, although moderate 
hyperkalaemia was seen in a small number of individuals.
Aliskiren, the direct renin inhibitor, has been trialled in 
people with type 2 diabetes and diabetic nephropathy, 
and no significant effect on renal outcomes has been 
noted, although a reduction in AER has been noted [68]. 
A small study of people with type 1 diabetes who were 
treated with aliskiren showed positive effects on renal 
haemodynamic indices and systemic vascular responses 
[69]. Furthermore, dual blockade with ACEI also showed 
beneficial effects on arterial compliance, flow-mediated 
dilatation and renal vasodilatation [70]. Further study of 
this group of drugs in type 1 diabetes is warranted.
Early studies of beta-blockade in people with diabetic 
nephropathy and type 1 diabetes suggest an equivalent 
effect to ACEI [71]. There is some suggestion that non-
dihydropyridine calcium channel blockade may have 
some of the benefits of dihydropyridine calcium chan-
nel blockers in the management of diabetic nephropathy 
[72].
Through their ability to reduce intraglomerular pres-
sure, blood pressure and uric acid levels, sodium glu-
cose cotransporter-2 (SGLT-2) inhibitors may offer the 
possibility of renal protection. One study suggests that 
SGLT-2 inhibitors can offer a reduction in glomerular 
hyperfiltration [73]. Recent analysis of the Empagliflozin, 
Cardiovascular Outcomes and Mortality in Type 2 Dia-
betes (EMPA-REG) study suggests significant renopro-
tection [74]. There is evidence from the Tandem 1 and 2 
studies that sotagliflozin can reduce blood pressure and 
UACR over 12 months, with similar renal haemodynamic 
changes seen with SGLT-2 inhibition in type 2 diabe-
tes [75]. However, the risk that these agents can cause 
ketoacidosis when they are given to people with type 1 
diabetes may limit their potential use in this group [76].
Use of dual blockade in people with type 1 diabetes 
and diabetic nephropathy Meta-analysis of a num-
ber of these studies of people with type 2 diabetes and 
nephropathy suggest a reduction in proteinuria, but at 
the expense of an increased risk of severe hyperkalaemia 
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and episodes of acute kidney injury (AKI) [77–79]. More 
recently, however, a large randomised controlled trial 
involving people with type 2 diabetes suggests that RAAS 
dual blockade has no benefit in terms of mortality, but 
that it may increase the risk of hyperkalaemia and AKI 
[80].
It is currently unclear whether there is a role for dual 
blockade in people who have type 1 diabetes and a nor-
mal eGFR (> 60 mL/min/1.73  m2) in whom albuminu-
ria is uncontrolled or increasing. While this may reduce 
albuminuria, there is no evidence of a reduction in other 
renal or cardiovascular end points.
In type 1 diabetes the pathogenic processes that occur in 
the development and progression of diabetic nephropa-
thy may be very different. Use of ACEIs is associated 
with a compensatory increase in plasma renin activity, 
and this effect may be ameliorated by the use of ARB 
drugs. There are, however, few studies on the use of dual 
RAAS blockade and outcomes in type 1 diabetes. One 
small study from India of 30 people who were treated for 
a short period with telmisartan and ramipril resulted in 
a reduction in UACR and blood pressure, with a slightly 
increased risk of hyperkalaemia [81]. A further small 
study of 21 people with type 1 diabetes showed that the 
addition of irbesartan to ACEI therapy in people with 
type 1 diabetes resulted in a 37% reduction in AER, along 
with significant reductions in blood pressure [82]. Fur-
ther studies of dual RAAS blockade in type 1 diabetes are 
needed.
When should RAAS blockade be stopped? The use of 
RAAS-blocking drugs in early pregnancy has been asso-
ciated with harm to the fetus, including cardiovascular, 
neurological and renal malformations [83], although 
more recent surveys do not suggest that there is a high 
risk of these problems occurring [84]. Pregnancy is 
associated with a high risk of progression of diabetic 
nephropathy in people with type 1 diabetes, and the ben-
efits of RAAS blockade in such individuals may outweigh 
the risks, but current advice is that RAAS-blocking drugs 
should be stopped when pregnancy is confirmed, and 
indeed when pregnancy is planned.
Drugs that block the RAAS reduce intraglomerular 
pressure and may lead to a rise in serum creatinine of 
up to 30%, which should then stabilise [85]. Some stud-
ies suggest that clinically significant renal artery steno-
sis may be quite common among people with diabetes, 
especially those with type 2 diabetes [86]. While the 
use of drugs that modulate the RAAS may increase the 
risk of deterioration in renal function in people with 
renovascular disease, in practice such deterioration is 
rare [87, 88].
RAAS blockade can lead to hyperkalaemia, which may 
be managed by dietary methods, diuretics or use of 
sodium bicarbonate. However, if the hyperkalaemia is 
severe and refractory to these measures, RAAS block-
ade may need to be stopped or reduced but this needs 
balanced with the loss of the benefits of proteinuria 
reduction and retardation of GFR declin e[89]. A further 
possible clinical scenario is someone with type 1 diabe-
tes having deteriorating renal function despite having 
well-controlled blood pressure on ACEI drugs. Once 
renal dysfunction continues to escape, despite optimal 
therapy, a decision may need to be made about cessation 
of ACEI therapy, especially if there may be a degree of 
ischaemic nephropathy, renovascular disease or postural 
hypotension. RAAS blockade may also increase the risk 
of AKI in people with diabetes, and advice to stop these 
drugs during periods of acute illness should be consid-
ered [90].
Hypertension management 
and renin‑angiotensin‑aldosterone system blockade 
in people with type 2 diabetes, nephropathy and/or early 
CKD stages 1–3
Recommendations (Table 3)
Diabetic nephropathy is the leading cause of end-stage 
kidney disease and it is characterised by a triad of per-
sistent albuminuria, hypertension and a decline in glo-
merular filtration rate (GFR). The presence of diabetic 
nephropathy increases cardiovascular morbidity and 
mortality and also increases progression to end-stage 
kidney disease [91–93]. After approximately 20–25 years, 
40% of people with type 2 diabetes develop evidence of 
diabetic nephropathy [94]. Both hypertension and hyper-
glycaemia are strong risk factors in determining pro-
gression of end-stage kidney disease and cardiovascular 
complications in diabetic nephropathy. Microalbuminu-
ria is one of the earliest manifestations of kidney disease 
in people with diabetes and it predicts increased cardio-
vascular morbidity and mortality in people with both 
type 1 and type 2 diabetes [95, 96]. The prevalence of 
microalbuminuria in people who have had type 2 diabe-
tes for 10 years is 25%, with an annual rate of progression 
to overt nephropathy of approximately 3% [94].
The risk of new as well as progressive microalbumi-
nuria is significantly associated with high blood pres-
sure [97]. In people with diabetes, cardiovascular and 
renal outcomes are adversely affected by the presence 
of hypertension and albuminuria [98]. Thus, controlling 
blood pressure and reducing albuminuria are important 
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treatment goals in diabetic nephropathy. Baseline blood 
pressure levels have been shown to be a powerful deter-
minant of subsequent kidney failure in large population-
based studies [99, 100]. Unlike those with type 1 diabetes, 
a high proportion of people with type 2 diabetes often 
have microalbuminuria and overt nephropathy at diag-
nosis. Without intervention, 20–40% of people with 
type 2 diabetes and microalbuminuria will progress to 
overt nephropathy. After 20 years of overt nephropathy, 
approximately 20% of those people will progress to end-
stage kidney disease.
The renin‑angiotensin‑aldosterone system
Dysregulation of the renin-angiotensin-aldosterone 
system (RAAS) plays a vital role in the pathogenesis of 
diabetic nephropathy, including pathogenesis of both 
micro- and macrovascular complications. Hyperglycae-
mia is associated with increased production of angio-
tensin II following RAAS over-activation in glomerular 
mesangial cells [101]. Thus, mechanisms to block the 
RAAS are an important therapeutic target in people with 
type 2 diabetes and nephropathy.
Hypertension in people with type 2 diabetes
In nearly one-third of people with type 2 diabetes, hyper-
tension is present at the time of their diagnosis. Hyper-
tension and type 2 diabetes may be related to underlying 
diabetic nephropathy, to co-existing essential hyperten-
sion or to renovascular disease, or it may be part of the 
complex insulin resistance syndrome. Hypertension in 
people with type 2 diabetes is generally associated with 
expanded plasma volume, increased peripheral vascular 
resistance and low renin activity [102].
The threshold for diagnosis and aims for hypertension 
control in people with type 2 diabetes vary according to 
national and international guidelines. In the UK, for the 
management of hypertension in people with diabetes and 
for those with a UACR of 70 mg/mmol (619.47 mg/g) or 
more and CKD, NICE guidance recommends a target 
blood pressure of < 130/80 mmHg [34]. The American 
Diabetes Association and the American Society of Neph-
rology recommend a blood pressure of < 140/90 mmHg 
in all individuals with type 2 diabetes and renal dis-
ease [103]. The Kidney Disease Improving Global 
Outcomes (KDIGO) guidelines recommend a blood 
pressure of ≤140/90 mmHg in those who have an AER 
of < 30 mg per 24 h (UACR > 3 mg/mmol [> 26.55 mg/g]), 
or ≤ 130/80 mmHg if the AER is > 30 mg per 24 h (UACR 
> 3 mg/mmol [> 26.55 mg/g]) in people with type 2 diabe-
tes [23].
The KDIGO 2020 guidance suggests a stricter control 
in all individuals with CKD targeting a systolic blood 
pressure < 120 mmHg using a standardised blood pres-
sure measurement technique, but acknowledges the 
lack of evidence in people who have diabetes and CKD 
[23].
There is little evidence base for recommending blood 
pressure targets in older people who have CKD. Most 
randomised controlled trials excluded people who were 
over 70 years of age (mean age 65 years: about 2.5% 
were older than 85 years of age) but some indirect infer-
ences can be drawn from studies of older populations 
who do not specifically have CKD. While there is some 
evidence regarding the treatment of high blood pres-
sure in much older people (that is, older than 80 years 
of age) from the Hypertension in the Very Elderly Trial 
(HYVET) [104], it applies to a blood pressure target of 
Table 3 Recommendations for people with type 2 diabetes and early CKD stages 1–3
Recommendations for renin‑angiotensin‑aldosterone system (RAAS) blockade and hypertension management in people with type 2 
diabetes, nephropathy and/or early chronic kidney disease (CKD)
    1. In people with type 2 diabetes and hypertension, we recommend salt intake of < 90 mmol per day (< 2 g per day of sodium – equivalent to 5 g of 
sodium chloride) (Grade 1C).
    2. In people with type 2 diabetes, CKD and urine albumin:creatinine ratio (UACR) < 3 mg/mmol (< 26.55 mg/g), we recommend that their target 
upright blood pressure should be < 140/90 mmHg, using antihypertensive therapy in the maximum tolerated doses (Grade 1D).
    3. In people with type 2 diabetes, CKD and UACR of > 3 mg/mmol (> 26.55 mg/g), we suggest aiming for a target upright blood pressure that is 
consistently < 130/80 mmHg, using antihypertensive therapy in the maximum tolerated doses (Grade 2D).
    4. There is no evidence to support either ACEI or ARB therapy as first‑line blood pressure lowering agents in comparison with other antihyperten‑
sive agents in people with type 2 diabetes, normal renal function and normal UACR (< 3 mg/mmol [< 26.55 mg/g]) (Grade 1A).
    5. We suggest that ACEIs (or ARBs if ACEIs are not tolerated) should be preferentially used in people with type 2 diabetes and CKD who have UACR 
> 3 mg/mmol (> 26.55 mg/g). We recommend that the dose of ACEI (or ARB) should be titrated to the maximum tolerated (Grade 2D).
    6. There is currently no evidence to support the role of home or ambulatory blood pressure monitoring in people with type 2 diabetes and CKD 
stages 2 and 3 (Grade 1D).
    7. There is currently no evidence to support the role of dual blockade of the RAAS in people with type 2 diabetes and CKD stages 1 to 3 (Grade 1B).
    8. Upright blood pressure targets should be set at no lower than 150/90 mmHg in those with type 2 diabetes who are aged 75 years or over (Grade 
2B).
    9. We recommend that people with type 2 diabetes should be advised to stop RAAS‑blocking drugs during periods of acute illness and restarted 
24–48 h after recovery from the illness (Grade 1C).
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150/80 mmHg in people with CKD who have an eGFR 
> 40 mL/min/1.73  m2.
The Swedish Trial in Old Patients with Hypertension 
(STOP Hypertension), which compared antihyperten-
sive treatments in preventing cardiovascular events in 
older people with diabetes (with a mean age of 75.8), 
supports an upright blood pressure target of no lower 
than 150/90 mmHg [105].
The KDIGO guidelines [23] suggest tailoring blood 
pressure treatment in older people with CKD to con-
sider age, comorbidities and other therapies, with a 
gradual escalation of treatment and close attention to 
electrolyte disorders, acute deterioration in kidney 
function, orthostatic hypotension and side effects of 
medications. Thus, it would seem reasonable to suggest 
a target upright systolic blood pressure of no less than 
150 mmHg in people with diabetes and CKD aged over 
75, taking into account side effects of medications and 
comorbidities.
The role of home and ambulatory blood pressure 
measurement
Although home and ambulatory blood pressure monitor-
ing is thought to be more representative of real-life blood 
pressure, their exact role in the diagnosis and manage-
ment of hypertension is unclear because a limited num-
ber of studies have been conducted in people with type 
2 diabetes who have CKD. However, it is recognised that 
high ambulatory blood pressure measurement systolic 
pressures and nocturnal non-dipping are associated with 
increased mortality and a decline in eGFR [106–108]. A 
small study of ambulatory blood pressure measurement 
in people with CKD, where 436 people who were hyper-
tensive were prospectively followed up, showed that it 
was much more accurate in predicting both renal and 
cardiovascular outcomes than office blood pressure [109]. 
Self blood pressure monitoring and ambulatory blood 
pressure measurement utilises oscillometric assessment 
of blood pressure at the elbow, which may be influenced 
by irregularities of pulse and high pulse pressures. In the 
UK, NICE guidelines recommend confirming hyperten-
sion with 24-h ambulatory monitoring (home BP moni-
toring where 24-h BP monitoring is unsuitable or not 
tolerated) before starting or increasing antihypertensive 
agents [34]. However, there is no direct evidence sup-
porting the use of either method for diagnosis of hyper-
tension in people with type 2 diabetes and CKD.
Lifestyle modification and impact on blood pressure
There is good evidence from a number of observational 
studies and randomised controlled trials that salt intake, 
weight and body mass index (BMI), exercise frequency 
and alcohol intake all have a significant impact on blood 
pressure levels [111–114]. Please see Table 4 for details.
Blood pressure lowering agents
In people with type 2 diabetes and CKD, three or more 
blood pressure agents are frequently required. There 
is increasing emphasis on individualisation of therapy. 
Eventually, the choice of agent is less important than 
the actual reduction in blood pressure that is achieved. 
There is little evidence to support the use of any particu-
lar agent in controlling blood pressure in CKD, nor are 
there any data to suggest the choice of second- or third-
line medications. The exception to this rule is the use of 
ACEIs or ARBs in people with CKD who have proteinu-
ria. ACEIs and ARBs have each been shown to be effec-
tive in delaying disease progression in people with type 2 
diabetes who have microalbuminuria or established dia-
betic nephropathy. There is a need to escalate to the max-
imal doses of ACEI or ARB in people who have diabetes 
and albuminuria before moving on to additional agents 
in order to achieve the required blood pressure targets. 
However, there is no evidence that these agents are effec-
tive in the primary prevention of diabetic nephropathy. 
The use of ACEIs or ARBs in people with type 2 diabe-
tes reduces microalbuminuria and retards the progres-
sive loss of renal function [61, 126–128]. ARBs are said to 
provide renoprotection over and above their blood pres-
sure lowering effect and short-term albuminuria reduc-
tion, and they are said to have a long-term favourable 
effect on renal prognosis [129] (Fig. 2).
Adherence with therapy
Non-adherence to antihypertensive treatment is com-
mon, with over 50% of people with apparent treatment 
resistance being non-adherent. This is especially so in 
those who are on multiple anti-hypertensive and other 
medications. Urine antihypertensive drug monitoring 
may help management of these individuals [130]. There-
fore, it is important to assess adherence especially in 
those not achieving blood pressure control despite taking 
3 or more antihypertensive agents in optimum doses.
RAAS blockade in people with type 2 diabetes 
without proteinuria
The use of RAAS blockade has significant benefits on 
cardiovascular and renal end points in people with diabe-
tes, independent of their blood pressure lowering effect, 
as shown in the Heart Outcomes Prevention Evaluation 
(HOPE) trial and the European trial on reduction of car-
diac events with perindopril in stable coronary artery dis-
ease [131, 132]. Whereas most guidelines favour the use 
of RAAS blockade as first-line treatment for people with 
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diabetes, hypertension and CKD (the American Diabetes 
Association, the American Society of Hypertension, the 
International Society of Hypertension) [133, 134], the 
European Society of Cardiology / European Society of 
Hypertension guidelines from 2013 and the eighth Joint 
National Committee on Prevention, Detection, Evalu-
ation and Treatment of High Blood Pressure from 2014 
recommend the use of any class of antihypertensive agent 
in people with diabetes in the absence of proteinuria, but 
suggest the use of RAAS blockade as first-line treatment 
only in the presence of proteinuria [135, 136].
This is based on the findings of 19 randomised con-
trolled trials that enrolled 25,414 participants with diabe-
tes, with a total of 95,910 patient years of follow-up. The 
results of this study from head-to-head randomised trials 
of RAAS blockade versus other antihypertensive agents 
failed to show superiority of RAAS blockade in people 
with diabetes and no proteinuria, and it suggested that 
any class of antihypertensive agents can be used in such 
individuals [137].
RAAS blockade in people with type 2 diabetes and proteinuria 
or microalbuminuria
In the UK, NICE guidance suggests offering a low-cost 
RAAS antagonist to people with CKD and diabetes 
who have: a UACR of 3 mg/mmol (26.55 mg/g) or more; 
hypertension and a UACR of 30 mg/mmol (265.49 mg/g) 
or more; or a UACR of 70 mg/mmol (619.47 mg/g) or 
more irrespective of hypertension or cardiovascular dis-
ease [138]. The favourable effects of RAAS blockade have 
been seen mainly in placebo-controlled trials [128, 131] 
and it has been postulated that the benefits of RAAS 
blockade on renal outcomes was probably as a result of 
their blood pressure lowering effect [139]. Several major 
trials have also demonstrated clear benefits of ARB use in 
people who have diabetic nephropathy [140, 141].
Use of dual blockade with ACEIs and ARBs in people with type 
2 diabetic nephropathy
ACEIs and ARBs block the RAAS at different sites and, in 
theory, dual blockade should provide more effective and 
complete blockade of the RAAS. The rationale for dual 
blockade is based on a phenomenon called ‘angiotensin 
II escape’, whereby evidence suggests that standard doses 
of ACEIs only offer a partial blockade of the angiotensin-
converting enzyme (ACE) [142]. It is said that enzymes 
such as chymase and cathepsin G can generate angioten-
sin II from angiotensinogen and other peptide substrates 
[143].
Several early studies had suggested that using a com-
bination of ACEI/ARB provided additional benefit in 
diabetic nephropathy in terms of surrogate albuminuria 
lowering. However, there remains substantial controversy 
about whether ACEIs and ARBs should be combined, 
given that most of these studies were small in size and 
short in duration.
In one meta-analysis of 10 trials, 156 participants 
received a combination of ACEI/ARB and 159 received 
an ACEI only (the duration of the study was 8–12 weeks). 
The combination was shown to reduce proteinuria at the 
expense of statistically and clinically significant reduc-
tions in eGFR. There was a suggestion that this decrease 
could be secondary to a reduction in blood pressure alone 
[77]. Most of the evidence base for combination dual 
blockade therapy initially came from studies about heart 
failure without any long-term data to support it (the can-
desartan and lisinopril microalbuminuria (CALM) study) 
[144]. This study evaluated the effects of dual blockade of 
candesartan and lisinopril on blood pressure and micro-
albuminuria in 199 people with type 2 diabetes (the dura-
tion of the study was 24 weeks). At the end of the study, 
combination therapy was found to be significantly more 
effective in reducing UACR (50% with combination, 24% 
with candesartan and 39% with lisinopril) and diastolic 
blood pressure (16.3 mmHg, 10.4 mmHg and 10.7 mmHg 
reduction, respectively) than either agent alone. Criti-
cisms of some of these studies were that there were no 
long-term follow-up data and that maximal doses of 
ACEIs were not used. It is also questionable whether the 
effects were specifically related to combination therapy 
or whether it was blood pressure reduction per se that 
was instrumental.
The ONTARGET study involved telmisartan and rami-
pril, and showed that the primary renal outcome (ie 
dialysis, doubling of serum creatinine and death) was 
similar for telmisartan (13.4%) and ramipril (13.5%), 
but was increased with combination therapy (14.5%, 
p = 0.037). The combination therapy, although associated 
with reduced albuminuria, caused the greatest decline in 
eGFR [145].
The KDIGO guidelines provide specific advice on dual 
blockade [23, 146]. In the UK, a NICE guideline explic-
itly states that combination therapy should not be used. 
The European Renal Best Practice working group has 
the same viewpoint as NICE [147]. The Canadian Health 
Education Programme’s (CHEP’s) 2009 recommendation 
advised against the use of dual blockade for people with 
non-proteinuric CKD or in people with diabetes and nor-
mal urinary albumin levels [148].
Overall, therefore, there is no current evidence to sug-
gest a beneficial effect of ACEI/ARB combination on the 
progression of diabetic nephropathy. Instead, combina-
tion therapy resulted in clinically significant decreases 
in eGFR and hyperkalaemia [149]. In one meta-analysis 
involving 17,337 people, the adverse effects of dual block-
ade revealed significantly high rates of discontinuation 
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because of a worsening of renal function, hyperkalaemia 
and symptomatic hypotension [150].
It is to be noted, however, that most studies published 
so far with regard to dual blockade have involved people 
with normal renal function who did not have a clinically 
significant rise in serum potassium or creatinine with 
dual blockade. However, in real life, widespread use of 
these agents would most likely involve people with resist-
ant hypertension with chronic renal impairment, and 
such individuals therefore will tend to have more of these 
side effects.
Aldosterone blockade in people with type 2 diabetic 
nephropathy
Aldosterone, the principal physiological mineralocor-
ticoid, has deleterious effects on both the cardiovascu-
lar system and the kidneys. There is evidence to suggest 
that initial RAAS blockade suppresses aldosterone levels. 
However, due to the phenomenon of aldosterone escape, 
aldosterone levels rise subsequently and can often exceed 
the baseline. ACEIs or ARBs do not directly block the 
effects of aldosterone at the receptor level [151].
Most evidence of the use of aldosterone antagonists 
like spironolactone, eplerenone and (more recently) 
finerenone come from heart failure trials. In one study 
of people who had type 2 diabetes with early nephropa-
thy and normal renal function, adding spironolactone 
to ACEI treatment was shown to be clinically useful and 
safe for people who showed aldosterone escape during 
ACEI treatment and who no longer showed maximal 
antiproteinuric effects of ACE inhibition [152, 153]. In 
another study of people with type 2 diabetes, macroal-
buminuria and serum creatinine of less than 160 μmol/l, 
treatment with spironolactone was found to be superior 
to cilazapril in reducing albuminuria [154]. In that study, 
50 mg of spironolactone was used and blood pressure 
Table 4 Lifestyle modification and impact on blood pressure
There is good evidence from a number of observational studies and randomised controlled trials that salt intake, weight and body mass index (BMI), exercise 
frequency and alcohol intake all have a significant impact on blood pressure levels [111–114]
Salt intake
The evidence base for the benefit of salt restriction in type 1 diabetes without advanced CKD is not strong. Reduced blood pressure has been found 
in some but not all short‑term studies, but an important long‑term observational study recorded higher dietary sodium intake was associated with 
higher all‑cause mortality and the development of ESKD [115, 116]. The KDIGO guidelines suggest lowering salt intake to < 90 mmol of sodium per 
day (< 2 g of sodium, which corresponds to 5 g of sodium chloride) [23]. High salt intake has a greater impact on blood pressure for people with 
diabetes, especially in those with CKD, due to their reduced ability to excrete salt load in their urine. Restricting salt intake lowers blood pressure by a 
moderate amount, as shown in a systemic review of seven trials where salt intake was restricted to 4–6 g (70–100 mmol), systolic blood pressure was 
reduced by 4.7 mmHg and diastolic blood pressure was reduced by 2.5 mmHg [117].
Given that salt restriction is inexpensive and it helps to lower blood pressure in the general population, despite a lack of availability of large‑scale, 
long‑term randomised controlled trials of salt restriction in people with CKD, there is no reason to believe that it would not be beneficial, although it 
would add to the dietary restrictions for managing diabetes. A low‑salt diet has been shown to reduce blood pressure and albuminuria in the short 
term in people who are on angiotensin receptor blockers (ARBs) and it may be a consideration for those with high blood pressure who have had a 
poor response to ACEIs or ARBs [118, 119].
Weight and BMI
Although abdominal obesity has been associated with higher blood pressure and use of antihypertensive therapy in type 1 diabetes [120], there is 
a dearth of evidence that weight reduction in type 1 diabetes reduces blood pressure, although this would be expected intuitively [121]. There is 
evidence of weight gain accompanied by increases in blood pressure in type 1 diabetes as a consequence of improved blood glucose control. The 
KDIGO guidelines recommend achieving or maintaining a healthy weight (BMI 20–25) [23]. Some observational studies, but not randomised trials, 
suggest that weight loss is likely to improve blood pressure in people with CKD, but there is a lack of high‑quality randomised controlled trials in this 
area.
Although obesity has been proposed to be a potential mediator of CKD progression, trials are conflicting and reliable data remain sparse. There is no 
role of weight loss diets in CKD either. Overall, achieving a healthy body weight will improve blood pressure levels and prognosis in CKD, particularly 
in the early stages (stages 1–2). Malnutrition needs to be avoided in more advanced stages of CKD [122].
Exercise programme
There is documentation that exercise training for 12 weeks or more reduces blood pressure in type 1 diabetes [123]. The KDIGO guidelines recom‑
mend undertaking an exercise programme that is compatible with cardiovascular health and tolerance, aiming for at least 30 min of exercise five 
times per week [23]. Increased physical exercise has a broad range of positive health outcomes in the general population. However, there are no 
randomised controlled trials in the CKD population: there are mostly observation studies. The benefits of exercise on blood pressure and on general 
health are likely to be similar in the CKD population as they are in the general population [124].
Alcohol intake
Evidence that alcohol intake affects blood pressure and reduction in intake helps blood pressure in type 1 diabetes is sparse. The KDIGO guidelines 
suggest limiting alcohol intake to no more than two standard drinks per day for men and no more than one standard drink per day for women [23]. 
Most of the effects of alcohol reduction are related to its effect on blood pressure; that is, suggesting that restricting alcohol intake would lower 
blood pressure. All the trial evidence is mostly related to the general population and there are no specific data on people with CKD, but the effects of 
alcohol intake on blood pressure are expected to be similar [125].
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of < 135/85 mmHg was pre-treated with atenolol and 
hydrochlorothiazide before randomisation. The authors 
concluded that the superior effect of spironolactone 
was independent of its hypotensive effect, although 15% 
of people had to discontinue spironolactone because of 
hyperkalaemia. However, since then this study publica-
tion has been retracted.
There is also evidence for additive effects of eplerenone 
(an aldosterone antagonist that does not have the oes-
trogenic side effects of spironolactone) like in the other 
aldosterone antagonist trials. Eplerenone was found 
to have beneficial effects on microalbuminuria in peo-
ple with type 2 diabetes when it was added to enalapril, 
although there was a much higher incidence of hyper-
kalaemia [155]. In the largest randomised controlled trial 
available using eplerenone, people with CKD, elevated 
urinary albumin levels and type 2 diabetes (177 people) 
received 50–100 mg of eplerenone and 91 people received 
a placebo. The addition of eplerenone to enalapril 20 mg 
per day resulted in a 40–50% reduction in AER by 
12 weeks in the eplerenone group, but by less than 10% in 
the placebo group. Small reductions in eGFR and systolic 
blood pressure were noted, as was hyperkalaemia [156].
More recently, finerenone, a novel non-steroidal min-
eralocorticoid antagonist with greater receptor selec-
tivity than spironolactone and eplerenone, has been 
shown to provide a greater reduction in proteinuria and 
end organ damage, compared with spironolactone or 
eplerenone. This was shown in the Mineralocorticoid 
Receptor Antagonist Tolerability – diabetic nephropathy 
(ARTS-DN) study involving 1501 participants who were 
already receiving an ACEI or ARB (the mean age of the 
participants was 64.2 years, 37% had a UACR > 30 mg/
mmol [> 265.49 mg/g] and 40% had an eGFR of 60 mL/
min/1.73  m2 or lower). Finerenone reduced the UACR at 
day 90 (relative to the baseline) more significantly than 
the placebo, and the pre-specified secondary outcome 
of hyperkalaemia leading to discontinuation was not 
observed either in the placebo or the finerenone group at 
various dosages. Also, there was no difference in terms of 
the incidence of a greater than 30% decrease of eGFR in 
either group. Thus 2.5–10 mg finerenone per day reduced 
albuminuria from the baseline in individuals with CKD 
and heart failure with a lower incidence of hyperkalae-
mia than spironolactone. It was postulated that this new 
mineralocorticoid receptor antagonist may be able to 
address the unmet medical need of safely managing albu-
minuria without effecting serum potassium in people 
with type 2 diabetes who have nephropathy. The strength 
of the study is that there was only a modest reduction in 
blood pressure at the highest dose of finerenone: quite 
unlike any other mineralocorticoid antagonist study in 
the past. The limitations of the study, however, include its 
short duration, the lack of a control group and that 60% 
of participants had an eGFR above 60 mL/min/1.73  m2, 
which put them at relatively low risk of hyperkalaemia 
[157].
The FIDELIO-DKD study showed that finerenone, a 
non-steroidal selective mineralocorticoid receptor antag-
onist, lowered the risks of CKD progression and cardio-
vascular events in people with CKD and type 2 diabetes 
treated optimally with renin-angiotensin system block-
ade. Of the 5734 people in the study, over 54% had eGFR 
< 45 mL/min/1.73  m2 and the median albumin creatinine 
ratio was 852 [IQR: 446–1634]. Finerenone, in doses of 
10–20 mg daily, was associated with improved renal 
(HR 0.82; 95% CI 0.73 to 0.93; NNT 29) and cardiovas-
cular outcomes (HR 0.86; 95% CI 0.75 to 0.99; NNT 42) 
compared with placebo. In the study cohort, finerenone 
reduced systolic blood pressure by 3 mmHg and the inci-
dence of hyperkalaemia of > 6 mmol/L was 10% with dis-
continuation due to serious hyperkalaemia of 2.5% [158, 
159].
From the above evidence, it may be reasonable in the 
future to consider adding in a selective mineralocorticoid 
receptor antagonist in people with DKD with a serum 
potassium of < 5 mmol with worsening albuminuria who 
are already on a maximal dose of ACEI or ARB.
Use of direct renin inhibitors in diabetic nephropathy
The use of aliskiren in people with type 2 diabetes and 
nephropathy has been shown to reduce AER, although 
no significant effects on renal outcomes have been noted. 
In the ALTITUDE trial, where aliskiren or a matching 
placebo was used on top of an ACEI or ARB in people 
with diabetic nephropathy, there were significant reduc-
tions in proteinuria but the trial was stopped early due 
to the low likelihood of ever demonstrating a benefit and 
the suggestion of an increased risk of non-fatal stroke, 
renal complications, hyperkalaemia and hypotension 
Fig. 2 Sick day rule
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[160]. The drug has subsequently been withdrawn from 
the market.
In another trial involving 599 participants, aliskiren 
was used either alone or in combination with losar-
tan for 6 months. This resulted in a reduction of UACR 
by 20% compared with the use of losartan alone. There 
were small differences in blood pressure between the two 
groups but no difference was found between the rates of 
adverse events [161]. Direct renin inhibitors are not cur-
rently recommended for use in diabetic nephropathy.
When should RAAS blockade be stopped?
Although ACEIs and ARBs are valuable blood pressure 
lowering agents in people with type 2 diabetes and CKD, 
they are not without their side effects.
Hyperkalaemia In the UK, NICE guidance suggests 
measuring serum potassium and eGFR before start-
ing RAAS blockade and repeating the measurements 
1–2 weeks after starting RAAS blockade and after each 
dose increase. NICE further says not to offer these 
agents if the person’s pre-treatment serum potassium 
is  > 5 mmol/L [34]. NICE guidance also suggests that 
these agents should be stopped if the serum potassium 
concentration increases to 6 mmol/L or more, and other 
drugs known to promote hyperkalaemia have been dis-
continued. However, recent NICE technology appraisals 
recommend the use of potassium binders, patiromer and 
sodium zirconium cyclosilicate, in outpatient care for 
people with persistent hyperkalaemia (≥6 mmol/L) and 
CKD stages 3b to 5 (non-dialysis), who are not taking an 
optimum dose of RAAS inhibitor because of hyperkalae-
mia [162, 163].
A drop in eGFR or an increase in serum creati‑
nine Given the basic pathophysiological mechanism of 
RAAS blockade, these agents cause a reduction in eGFR 
and urinary albumin excretion through efferent and 
afferent glomerular arteriolar dilatation, with a result-
ant fall in intra-glomerular blood pressure. A reversible 
reduction of eGFR of up to 30% can be expected. Greater 
reductions may indicate underlying renal artery stenosis.
NICE guidance states that if there is a decrease in eGFR 
of > 25% or an increase in serum creatinine of > 30% with 
RAAS blockade, renal function tests need to be repeated 
within 1–2 weeks. If the eGFR drops by 25% or more, or 
there is a change in serum creatinine by 30% or more, 
NICE guidance suggests conducting further investiga-
tions to identify a cause of renal deterioration, such as 
sepsis, volume depletion, other acute illneses such as 
heart failure and myocardial infarction, or non-steroidal 
inhibitor / potassium-sparing diuretic use. If no other 
cause for the deterioration in renal function is found, it 
is recommended to stop the RAAS blockade or reduce 
the dose to a previously tolerated lower dose, and add an 
alternative antihypertensive medication if required [138, 
164, 165].
Consideration should also be taken where someone’s 
baseline eGFR is already below 30, especially in those 
with congestive cardiac failure, where there may be a 
broader benefit terms of left ventricular function.
Pregnancy Given the potentially teratogenic nature of 
RAAS blockade drugs, the KDIGO guidelines suggest 
that the use of these drugs in women of childbearing age 
should be balanced with the risk of pregnancy [166].
Inter‑current illness There are risks of large reductions 
in eGFR with RAAS blockade, particularly during inter-
current illness or with intravascular fluid depletion (diar-
rhoea, vomiting and high fever). It is therefore recom-
mended to reduce the dose or to hold off ACEI or ARB 
use until recovery is made, because ensuing hypotension 
may cause an acute decline in eGFR in people with type 
2 diabetes with CKD who are taking ACEIs or ARBs. It 
is recommended that people with type 2 diabetes should 
be advised to stop RAAS-blocking drugs during periods 
of acute illness and restarted 24–48 h after recovery from 
the illness. These precautions should especially be taken 
if an individual is on a combination involving non-steroi-
dal anti-inflammatory drugs or diuretics [167–170].
Other agents for blood pressure lowering in people with type 
2 diabetes and nephropathy
Most of the evidence for the use of other antihyperten-
sive agents (apart from ACEIs or ARBs) is extrapolated 
from the general population and there is little evidence of 
their specific use or rationale in people with type 2 diabe-
tes and CKD.
Calcium channel blockers There is good evidence to 
suggest that non-dihydropyridine calcium channel block-
ers (verapamil and diltiazem) reduce proteinuria [72, 
171]. A multicentre trial in people with type 2 diabetes 
and nephropathy suggested that adding a non-dihydro-
pyridine calcium channel blocker to an ACEI-based 
regime can be effective at lowering residual albuminuria 
with or without a significant reduction in systolic blood 
pressure [172]. Thus non-dihydropyridine calcium chan-
nel blockers can be used as a valid additive or alternative 
to ACEIs or ARBs in people with type 2 diabetes, suggest-
ing that their renal protective effects are over and above 
blood pressure lowering alone. Diltiazem and verapamil 
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can induce bradycardia and heart block in combination 
with beta blockers; dihydropyridines such as amlodipine 
are more appropriate alongside beta blocker use.
Beta blockers Much of the bad publicity about beta 
blockers is related to the use of atenolol, which has been 
the most frequent comparator in most randomised con-
trolled trials. However, beta blockers are not a homog-
enous class of drug, and agents like celiprolol, carvedilol 
and nebivolol have vasodilating properties and do not 
share the negative properties of atenolol (that is, a lack 
of 24-h antihypertensive effect and withdrawal effects). 
In the UK, NICE guidance does not favour beta blockers 
as the first-line choice in the treatment of hypertension in 
the general population. There is evidence that in people 
with type 2 diabetes with advanced CKD and a high risk 
of sudden death, beta blockers may prove to be beneficial 
by lowering heart rate apart from lowering sympathetic 
hyperactivity and preventing ventricular arrhythmias 
[173, 174]. A meta-analysis of beta blockers used to treat 
CKD supports the use of beta blockers in people with 
CKD who have heart failure, but it does not provide evi-
dence of their efficacy in preventing mortality, cardiovas-
cular events or renal disease progression in people with 
CKD who do not have heart failure [175].
Diuretics In the UK, NICE guidance prefers agents 
with a thiazide-like action such as chlorthalidone and 
indapamide, and this is relevant for individuals with 
CKD who have type 2 diabetes [34]. Chlorthalidone 
was used in the largest randomised controlled trial in 
hypertension (the Anti-hypertensive and Lipid-Low-
ering Treatment to Prevent Heart Attack Trial (ALL-
HAT) study) [176]. The evidence base for indapamide 
is through the Hypertension in the Very Elderly Trial 
(HYVET) [104]. The PROGRESS trial involved a com-
bination of indapamide and perindopril, and was shown 
to reduce the risk of stroke [177]. The additional advan-
tage of indapamide is its potassium-depleting effect, and 
this may be convenient when it is combined with ACEIs 
or ARBs, particularly in those with type 2 diabetes who 
have CKD. Loop diuretics like furosemide would be par-
ticularly useful for treatment of hypertension in people 
with type 2 diabetes with advanced CKD stages 4–5, as 
fluid overload is invariably a major contributing factor in 
such individuals.
Alpha blockers Drugs like doxazosin could be an 
adjunctive treatment for hypertension in people with 
type 2 diabetes and CKD in whom other therapies have 
failed or not been tolerated, particularly if symptoms of 
prostatic hypertrophy are present. Alpha blockers are 
generally not recommended first line because of the 
common side effects of postural hypotension, tachycardia 
and headache.
Centrally acting alpha adrenergic agonists Centrally 
acting alpha adrenergic agonists cause vasodilation by 
reducing sympathetic outflow from the brain. Common 
agents in this category are methyldopa, clonidine and 
moxonidine. Doses of methyldopa and clonidine are not 
generally required to be reduced in people with CKD. 
Although moxonidine is extensively excreted by the kid-
ney, one randomised controlled trial that compare it with 
a calcium channel blocker added to an ACEI or ARB 
plus a loop diuretic indicated that it is safe to be used in 
advanced CKD [178]. Common side effects of moxoni-
dine include headache, tiredness, dizziness and gastro-
intestinal symptoms, which occur in 10–15% of people. 
These agents should not be used as a first-line treatment, 
but they are generally used in conjunction with other 
antihypertensive agents in people with type 2 diabetes 
who have hypertension.
Agents shown to have benefit in blood pressure reduction 
and outcomes but not currently licensed for this indication
Endothelin a receptor antagonists Atrasentan, an 
endothelin A receptor antagonist, 0.75 mg daily, was 
able to reduce systolic blood pressure significantly in 
2648 people who were proteinuric with diabetes and 
CKD and with eGFR25–75 mL/min/1.73  m2. They were 
responsive to the drug by 6.1 mmHg (95% CI 5.6 to 6.7) 
and by 1.2 mmHg (95% CI 0.7–1.7) in the subsequent 
RCT which led to lower the risk of ESKD and doubling 
of serum creatinine by 35%; HR 0.65 (95% CI 0.49–0.88). 
Therefore, endothelin A receptor antagonists are promis-
ing agents in lowering BP but further studies in high-risk 
advanced CKD individuals are necessary before clinical 
use [179].
Sodium glucose cotransporter‑2 (SGLT‑2) inhibitors In 
the CREDENCE trial systolic blood pressures were lower 
in the canagliflozin group by 3.30 mmHg (95% CI 2.73 to 
3.87) and diastolic blood pressure by 0.95 mmHg (95% 
CI, 0.69–0.92) compared with the placebo group.178 
Despite the greater reduction in eGFR in the first 3 weeks 
in the canagliflozin group (− 3.17 mL/min/1.73  m2, 95% 
CI, − 3.87 to − 2.47) the longer term decline in kid-
ney function was slower in the canagliflozin group by 
2.74 mL/min/1.73  m2 per year (95% CI, 2.37, 3.11). This 
phenomenon is very similar to what is seen with RAASi 
and hence SGLT-2i may have a similar mechanism of 
action. There was also a 31% reduction of UACR in the 
canagliflozin group. The majority of the participants 
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had CKD stage 3 with mean eGFR at baseline of 
56.2 ± 18.2 mL/min/1.73  m2 with significant albuminuria 
300–5000 mg/g. However, 373 people reached the study 
endpoints of end-stage kidney disease, doubling of serum 
creatinine and renal death indicating a group of people 
with CKD stages 4 and 5 benefited from continued cana-
gliflozin even at eGFRs < 30 mL/min/1.73  m2 [180, 181].
Hypertension management 
and renin‑angiotensin‑aldosterone system blockade 
in people with type 2 diabetes, nephropathy and/or later 
stage CKD stages 4 and 5 (non‑dialysis)
Recommendations (Table 5)
Advanced stages of CKD, particularly stages 4 and 5, are 
associated with hyperkalaemia, fluid retention and anae-
mia requiring erythropoiesis stimulating agents which 
may further increase blood pressure. Hyperkalaemia 
[> 5.5 mmol/L] is present in 31% of people in advanced 
kidney disease clinics [182]. Hyperkalaemia is more com-
mon in people with CKD and diabetes than in those with 
CKD without diabetes [183]. In a blood pressure con-
trol trial in people with CKD the risk of hyperkalaemia 
was seven times higher in people with eGFR < 30 mL/
min/1.73  m2 compared with eGFR > 50 mL/min/1.73  m2 
and seven times higher with ramipril compared with 
amlodipine [184]. Hence BP control in people with dia-
betes and CKD stages 3–5 particularly with an ACEI or 
ARB requires careful monitoring and management of 
serum potassium. The prevalence of primary aldosteron-
ism in people with diabetes and resistant hypertension is 
14%, and this should be considered when BP is difficult to 
control [185].
Identification and monitoring of people with diabetes 
and CKD stages 4 and 5
The rise in blood pressure in people with diabetic 
nephropathy is associated with higher mortality and 
increased risk of macro and micro vascular compli-
cations [3, 186]; and treatment lowers cardiovascular 
events, strokes and all-cause mortality [187–189]. Hence 
people with diabetes and CKD stages 4–5 should be reg-
ularly screened to identify and manage high blood pres-
sure. It is necessary to identify those with hypertension 
early to avoid delays in treatment; while avoiding unnec-
essary anxiety and the inconvenience related to frequent 
visits to doctors and nurses. With the use of RAAS block-
ers, monitoring of serum potassium is important to avoid 
dangerous hyperkalaemia [190]. Frequent blood testing 
will also identify people who are more likely to progress 
to renal replacement therapy [191]. Most clinical trials 
have monitored individuals’ clinical characteristics and 
laboratory values every 3 to 12 months and have demon-
strated identification of new onset hypertension, protein-
uria and hyperkalaemia in this time frame [184, 192, 193]. 
The recommendations for monitoring by NICE are: twice 
a year for CKD stage 3a, ≥2 times a year for CKD stage 
3b, 3 times a year for CKD stages 3 and 4 and ≥ 4 times 
a year for CKD stage 5. However, this can be tailored 
according to the individual’s needs [138]. During the 
first consultation, ambulatory (or home) blood pressure 
monitoring should be offered to confirm the diagnosis of 
hypertension [34]. Measurement of sitting and standing 
blood pressure may be useful to diagnose postural hypo-
tension which may contribute to symptoms and stand-
ing blood pressure may be a better target. Blood pressure 
should be measured by standardised technique in a quiet, 
Table 5 Recommendations for people with type 2 diabetes and CKD stages 4 and 5 (non‑dialysis)
Recommendations for hypertension management and RAAS blockade in people with type 2 diabetes and CKD stages 4 and 5 (non‑
dialysis)
    1. We recommend regular monitoring of blood pressure, urine albumin, blood electrolytes and kidney function in people with diabetes and CKD 
stages 4 and 5 (Grade 1B).
    2. We suggest, if blood pressure is uncontrolled, electrolytes are abnormal, or kidney disease is progressive they should be monitored 2 to 4 times a 
year depending on the stage of CKD and the individual’s need (Grade 1B).
    3. We recommend initiation of antihypertensive agents in people with diabetes and CKD stages 4 and 5, and UACR < 3 mg/mmol (< 26.55 mg/g) 
when blood pressure is ≥140/90 mmHg and aim for a target blood pressure of < 140/90 mmHg during therapy (Grade 1B).
    4. We suggest initiation of antihypertensive agents in people with diabetes and CKD stages 4 and 5 and UACR > 3 mg/mmol (> 26.55 mg/g) when 
blood pressure is ≥130/80 mmHg and aim for a target blood pressure < 130/80 mmHg (Grade 2C).
    5. We recommend the use of angiotensin converting enzyme inhibitor (ACEI) (or angiotensin receptor blocker (ARB) if ACEI is not tolerated) as the 
first‑choice blood pressure lowering agent in people with diabetes and CKD stages 4 and 5 and micro/macroalbuminuria (Grade 1B).
    6. We do not recommend the use of combinations of ACEIs and ARBs in people with diabetes and CKD stages 4 and 5 (Grade 2B).
    7. We suggest dietary advice, correction of acidosis and loop diuretic therapy to lower serum potassium as necessary in people with diabetes and 
CKD stages 4 and 5 for safe use of ACEI (or ARB) (not graded).
    8. Consider the use of novel potassium binders in people with diabetes and CKD stages 3b to 5 (non‑dialysis) if potassium is 6 mmol/L or higher, 
for continued and safe use of ACEi (or ARB), or where people are not taking or are only taking sub maximal RAAS blockade because of hyperkalaemia 
(not graded).
    9. We recommend dietary input to follow low sodium diet in all individuals with diabetes, advanced chronic kidney disease and high blood pres‑
sure (Grade 1B).
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comfortable environment, on an outstretched supported 
arm, using a properly calibrated machine with an appro-
priate cuff as suggested by the BIHS.
Target blood pressure in people with diabetes and CKD 
stages 4 and 5, with or without significant albuminuria [UACR 
> 3 mg/mmol (> 26.55 mg/g)]
Several observational and prospective studies have 
demonstrated the significant impact of blood pressure 
on mortality, cardiovascular events and renal failure in 
people with diabetes and CKD [3]. Among those from 
advanced CKD clinics, high blood pressure (particularly 
systolic) is associated with progression to dialysis and 
mortality [194].
Very few studies have examined the impact of tight 
blood pressure control in people with diabetes and CKD 
stages 4 and 5. Some studies have examined the role of 
intensive blood pressure lowering in people with diabe-
tes and mild CKD; a small proportion of people demon-
strating the advantage of lowering blood pressure below 
140/90 mmHg but not below 130/80 mmHg [195]. In a 
study of African-American people with non-diabetes 
CKD and eGFR 20–65 mL/min/1.73  m2 the tight blood 
pressure [achieved 128/78 mmHg] control arm suffered 
similar renal end points compared to less tight blood 
pressure [achieved 141/85 mmHg] control arm [196]. 
In the SPRINT trial, which included 2646 non-diabetic 
participants with eGFR 20–60 mL/min/1.73  m2, inten-
sive blood pressure control [target < 120 mmHg] was not 
associated with improved composite renal outcomes, 
compared with standard control in those with chronic 
kidney disease [target < 140 mmHg] [193]. However, no 
participants with diabetes were included in the SPRINT 
trial. In another large randomised controlled trial of high 
risk individuals with diabetes (ACCORD-BP), the inten-
sive blood pressure control arm [target SBP < 120 mmHg; 
achieved 119 mmHg] was associated with a higher chance 
of having a eGFR < 30 mL/min/1.73  m2 [99 vs 52 events; 
p  < 0.001] than the normal blood pressure control arm 
[target SBP < 140 mmHg; achieved 133 mmHg], without 
any benefit in reducing cardiovascular complications 
[192]. This trial excluded people with creatinine above 
1.5 mg/dL (approximate eGFR 50 mL/min/1.73  m2), and 
mean creatinine at baseline was 0.9 mg/dL (approximate 
eGFR 91 mL/min/1.73  m2). In the same study there was 
no difference in new onset microvascular complications 
with intensive blood pressure control and half of the peo-
ple who had progressive renal disease did not have albu-
minuria [197]. However, a pooled analysis of SPRINT and 
ACCORD-BP with 14,094 people followed for 3.26 years 
suggests a 18% risk reduction of cardiovascular events 
and cardiovascular deaths [198]. However, lowering 
blood pressure < 130/80 mmHg may be associated with 
unwanted side effects and individuals should be involved 
in the decision-making process [199].
Several studies have shown that presence of signifi-
cant albuminuria is associated with poor cardiovascular 
outcomes and reduction of albuminuria is associated 
improvement [200]. Analysis of data from the RENAAL 
study, a trial of ARB in diabetic nephropathy, demon-
strated an approximate doubling of risk of cardiovascular 
outcome with high albuminuria at baseline (UACR > 3 g/g 
compared with < 1.5 g/g of creatinine), and 18% lowering 
of the cardiovascular events with 50% lowering of albu-
minuria [201]. The evidence for better outcome with 
tighter blood pressure control with high albuminuria is 
mainly observational and derived from post hoc analysis 
of large randomised controlled trials. The RENAAL study 
which included a significant number of people with CKD 
stages 3 and 4 demonstrated baseline higher risk with 
SBP > 140 mmHg (no difference between < 130 compared 
with 130–140 mmHg), and a 23% risk reduction for ESKD 
with achieved BP < 140/90 compared with > 140/90 [202]. 
Analysis of data from two large ARB trials (IDNT and 
RENAAL) indicate that the benefits of cardiovascular 
risk reduction exist with SBP < 130 mmHg (particularly 
when albuminuria was reduced to lower levels). However, 
the risk increased with SBP < 120 mmHg [203]. Post-hoc 
analysis of IDNT trial demonstrated a benefit in reduc-
tion of heart failure events with SBP < 130 mmHg but 
possible increased risk with SBP < 120 mmHg; and a DBP 
< 85 mmHg was associated with increased risk of MI and 
CHF [204]. Hence there is a suggestion of better cardio-
vascular outcomes with reduction of systolic blood pres-
sure below 130 mmHg but not below 120 mmHg. With 
target blood pressure < 130/80 mmHg in the STENO 2 
randomised trial there was reduction in cardiovascular 
mortality; however most participants had CKD stages 
1 and 2 and in the presence of other interventions it is 
difficult to tease out the effect of tight BP control [205]. 
Thus a lower target for blood pressure < 130/80 mmHg 
may be suggested in people with significant albuminu-
ria as suggested by other guidelines (KDIGO/NICE) but 
stronger evidence is needed [138, 206]. The draft KDIGO 
2020 guidelines suggest a lower blood pressure target 
< 120 mmHg systolic in all individuals with CKD with 
diabetes irrespective of the degree of proteinuria, while 
acknowledging that the degree of evidence in support of 
tighter control is low (evidence grade 2B), the clinical risk 
of adverse events with low blood pressure target, par-
ticularly when measured in non-standardised manner is 
high; thus allowing clinicians to target higher blood pres-
sure when necessary [23]. This guideline proposes a tar-
get blood pressure of < 140/90 mmHg for all individuals 
with diabetes, no significant proteinuria and CKD stages 
4 and 5, as improved cardiovascular outcomes have been 
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demonstrated in randomised controlled trials with blood 
pressures < 140/90, but inconsistent results with lower 
targets. Whereas the proposed target is < 130/80 mmHg 
is for people with significant proteinuria as it is associ-
ated with reduction in proteinuria in diabetic kidney 
disease which may improve renal and cardiovascular 
outcomes.
Renin‑angiotensin system blockade for blood pressure 
control in people with diabetes and CKD stages 4 and 5
In a study of African-American people without diabe-
tes and with eGFR 20–65 mL/min/1.73  m2, use of the 
ACEI ramipril was associated with significant reduction 
in clinical composite outcome compared to metopro-
lol [22% (95% CI, 1–38%; p = 0.04)] or amlodipine [38% 
(95% CI, 14–56%; p = 0.004)] [196]. In a randomised con-
trolled trial of people with diabetes [30% with mild CKD] 
use of enalapril was associated with fewer cardiovascu-
lar events compared with nisoldipine [5 vs. 25; p < 0.001] 
[207]. In a recent meta-analysis of 119 trials, use of ACEI 
or ARBs in 64,768 participants with CKD was associated 
with reduced risk of kidney failure compared with other 
antihypertensives [odds ratios of 0.65 (95% CI 0.51–0.80) 
for ACEIs and 0.75 (95% CI, 0.54–0.97) for ARBs] [208]. 
Hence ACEIs should be used in people with diabetes and 
CKD stages 4 and 5, with careful monitoring of kidney 
function and serum potassium. In a meta-analysis treat-
ment with ACEIs in people with diabetes was shown to 
reduce reduce all-cause mortality, cardiovascular mor-
tality and cardiovascular events but not with ARBs [209, 
210]. A recent network meta-analysis showed reduc-
tion in ESKD with ACEI and/or ARB but did not dem-
onstrate overall survival benefit [211]. Thus there is 
strong evidence for use of ACEI/ARB as the first choice 
antihypertensive in people with diabetes and CKD with 
eGFR > 30 mL/min/1.73  m2. Participants in large ran-
domised controlled trials of people with diabetes had 
eGFR no lower than approximately 25 mL/min/1.73  m2 
in REENAL and 38 mL/min/1.73  m2 in micro HOPE [202, 
212]. Though hyperkalaemia and rapids decline in kid-
ney function is an issue in people with advanced CKD, 
recent analysis of 3909 individuals with CKD stages 4–5 
suggested continuing treatment with ACEI or ARB was 
associated with cardiovascular benefit. The impact of 
withdrawal of ACEI or ARB on progression of CKD is 
being investigated by the STOP ACE randomised con-
trolled trial [213, 214].
In a study of combination therapy of ACEI with ARB 
in people who have diabetes with UACR  > 33.9 mg/
mmol (300 mg/g) and eGFR 30–90 mL/min/1.73  m2, 
there was no difference in mortality but a significant in 
increase in hyperkalaemia [6.3 events vs. 2.6 events per 
100 person-years with monotherapy; p < 0.001] and acute 
kidney injury [6.7 vs. 0.2 events per 100 person-years, 
p < 0.001] [80]. Combination of ACEI with ARB was not 
associated with benefit in primary endpoints but more 
side effects hence should be avoided. However, a network 
meta-analysis suggested a potential benefit of dual block-
ade if it can be administered safely, hence the need for 
further trials of dual-blockade in diabetes patients with 
CKD and albuminuria [146, 211].
A rise in serum creatinine up to 30% is not uncommon 
and rise of potassium by 0.5 mmol/L is not uncommon 
with initiation of ACEI therapy [85]. A post-hoc analysis 
of the ACCORD-BP trial demonstrates > 30% rise in cre-
atinine identifying patients at risk for cardiovascular and 
all-cause mortality, but only associated with adverse renal 
outcome in the standard arm and not intensive therapy 
arm [198]. Thus a mild rise in creatinine may not require 
any change in planned therapy. Hence no modification of 
ACEI or ARB therapy is necessary if the rise in creatinine 
from baseline is < 30% or drop in eGFR is < 25%.
Addition of spironolactone and further inhibition of 
the renin-angiotensin-aldosterone system may provide 
additional anti-proteinuric effect as seen in small studies 
and merits further large trials with more clinically rele-
vant outcomes [215].
Management of hyperkalaemia with renin‑angiotensin 
system blockade in people with diabetes and CKD stages 
4 and 5
Hyperkalaemia is common in people with diabetes 
and CKD. It is very common (> 30%) in advanced CKD 
patients managed in the low-kidney-clearance clinics 
[182]. The cause of such hyperkalaemia can be multifac-
torial; including renal failure, type 4 renal tubular acido-
sis, diet and drugs. The presence of hyperkalaemia limits 
the use of renin-angiotensin-axis inhibitors. The chroni-
cally high potassium levels have been traditionally con-
trolled with restricted diet, diuretics and avoiding drugs 
that cause hyperkalaemia.
Traditionally hyperkalaemia has been managed with 
dietary potassium restriction and correction of aci-
dosis, if present with bicarbonate therapy. However, 
the new potassium binding agents have been tested 
for safety and efficacy in randomised controlled tri-
als for management of chronic hyperkalaemia in CKD 
patients. They cause an early and sustained lowering 
of potassium in people with CKD on RAAS blocker 
therapy [216]. In 306 individuals with diabetes and 
CKD stages 3 to 4, treated with RAAS blockade [ACEI/
ARB ± spironolactone], use of a novel potassium bind-
ing polymer (patiromer) was associated with signifi-
cant and sustained decrease in serum potassium over 
52 weeks [217]. In a study of 237 participants with CKD 
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the same potassium binder was able to reduce serum 
potassium by 1 mmol/L over 4 weeks [218]. In another 
study of 243 participants over > 50% of whom had dia-
betes, the potassium binder achieved approximately 
1 mmol/L reduction in serum potassium over 4 weeks 
in individuals with and without heart failure [219]. The 
treatment with patiromer was associated with decrease 
aldosterone levels and decreased blood pressure which 
may provide additional benefits [220]. However, the 
above-mentioned trials are of short duration and the 
possible ACEI or ARB use facilitated with potassium 
binders, has not been shown to improve cardiovascu-
lar events or mortality. However, in the recent AMBER 
study, in people with resistant hypertension and 
chronic kidney disease (50% with diabetes), patiromer 
enabled more individuals to continue treatment with 
spironolactone with less hyperkalaemia [221, 222].
Novel potassium binders may be useful in diabetes 
patients with chronic kidney disease, particularly when 
associated with left ventricular dysfunction. Recent NICE 
technology appraisals recommend the use of potassium 
binders, patiromer and sodium zirconium cyclosilicate, 
in outpatient care for people with persistent hyperkalae-
mia (> 6 mmol/L) and CKD stages 4 to 5 (non-dialysis), 
who are not taking an optimised dosage of RAAS inhibi-
tor because of hyperkalaemia [162, 163].
Non‑pharmacological management of hypertension 
in people with diabetes and CKD stages 4 and 5
In randomised controlled trials dietary sodium restric-
tion in people with CKD is associated with significant 
lowering of blood pressure, but longer-term benefits of 
dietary intervention are unknown [223, 224]. The dietary 
advice is best provided by a trained dietitian due to the 
complex and frequently changing needs in this group of 
people. Individuals with CKD stages 4 and 5 would ben-
efit most from this and are best managed in a multidisci-
plinary clinic with expert nurses and dietitians. Dietary 
potassium restriction is useful but clinical trial evidence 
is yet to be generated. Regular exercise tends to improve 
quality of life, eGFR decline, HbA1c, BMI without any 
adverse effects in people with diabetes and CKD stages 
3–5 [225]. People should be also advised to quit smoking 
which is known to improve blood pressure in hyperten-
sive individuals. Please also see Table 4.
Hypertension management 
and renin‑angiotensin‑aldosterone system blockade 
in people with diabetes and CKD stage 5 on dialysis (5D)
Recommendations
Hypertension is a common finding in people with dia-
betes as well as those with CKD stage 5D. Elevated 
blood pressure [226, 227], diabetes [3, 228] and CKD 
[229–231] are all major risk factors for adverse cardio-
vascular events.
According to the UK Renal Registry and the European 
Renal Association – European Dialysis and Transplant 
Association (ERA-EDTA) Renal Registry, 23–36% of 
incident dialysis patients had diabetes as their primary 
renal disease [232, 233]. People with diabetes who are 
on haemodialysis have a poorer survival rate compared 
with dialysis patients who do not have diabetes [234, 
235]. This is mainly due to cardiovascular disease [236–
238]. Control of hypertension in hypertensive dialysis 
patients was shown to be associated with improved 
survival [239].
It is therefore logical that, in order to reduce cardio-
vascular risk and improve survival, optimal blood pres-
sure control should be achieved in people with diabetes 
and CKD stage 5D. However, there is insufficient evi-
dence from data in the published literature to decide 
how best to manage blood pressure in people with dia-
betes who are on dialysis. This is in part because peo-
ple with CKD, including those with stage 5D, are ‘often’ 
excluded from clinical trials of hypertension.
There are emerging, although not consistent, data 
delineating how best to measure blood pressure, to 
target blood pressure and to use pharmacological and 
non-pharmacological therapies to optimise blood 
pressure control in people with CKD stage 5D. How-
ever, these data are not specific to the population with 
diabetes.
Furthermore, blood pressure control in people who 
are on dialysis is complex. Many factors affect blood 
pressure in people who are on dialysis, including fluid 
status, salt intake, sympathetic nervous system activity 
and the renin-angiotensin-aldosterone system (RAAS). 
People with diabetes who are undergoing haemodi-
alysis often have autonomic dysfunction [240], which 
increases the risk of cardiovascular instabilities dur-
ing dialysis. Haemodialysis causes severe orthostatic 
reduction in cerebral blood flow velocity in people 
with diabetes and may subsequently increase the risk 
of cerebrovascular injury post haemodialysis [241]. This 
makes management of hypertension in people with 
diabetes who are on dialysis even more challenging 
(Table 6).
Blood pressure measurement in people with diabetes who 
are on haemodialysis
In UK dialysis units, measuring pre- and post-dialysis 
blood pressure is the standard technique for moni-
toring blood pressure in people who are on dialysis. 
However, blood pressure measurement in people who 
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are on haemodialysis is complex. There are conflicting 
data as to whether blood pressure measurements pre- 
and post-dialysis are predictive of interdialytic blood 
pressure in comparison with ambulatory blood pres-
sure measurement and/or home blood pressure meas-
urement. Ambulatory blood pressure measurement is 
considered to be the most accurate method for study-
ing blood pressure in people who are on haemodialysis 
[242] and in the general population it provides a more 
accurate prediction of cardiovascular outcomes in com-
parison with clinic blood pressure measurement [243]. 
A meta-analysis of 18 studies that involved 692 people 
who were on dialysis showed that pre-dialysis blood 
pressure and post-dialysis blood pressure are imprecise 
estimates of interdialytic ambulatory blood pressure 
[244]. People with diabetes were included in most of 
these studies [236, 242] at a rate that varied from 8 to 
54%. The presence of diabetes made no difference to the 
outcome.
In an extensive review of the literature by Agarwal 
et al [245], evidence from several studies was presented 
to show that, in people on haemodialysis, blood pressure 
measurement at home [246] or ambulatory blood pres-
sure measurement [247, 248] are stronger predictors 
of LVH [249] and mortality [250, 251] compared with 
blood pressure obtained in the dialysis unit. In predict-
ing LVH, weekly average home systolic blood pressure 
measurement was similar to interdialytic ambulatory 
blood pressure measurement and was superior to pre-
dialysis and post-dialysis blood pressure measurement 
[249]. In contrast to home blood pressure measurement, 
ambulatory blood pressure measurement can diagnose 
nocturnal non-dipping and offers great insights into cir-
cadian rhythm [252]. Loss of diurnal rhythm, which is 
a feature of diabetic nephropathy, is reported to lead to 
worse outcomes in people who are on dialysis [247]. In a 
study of 89 people who are on haemodialysis by Liu et al, 
the incidence of cardiovascular events and deaths were 
3.5–9 times higher in non-dippers (that is, those who lose 
their diurnal blood pressure variation) compared with 
dippers [253]. Ambulatory blood pressure measurement 
can therefore be advantageous in selecting high-risk 
individuals and can guide treatment. However, to date, 
there have been no specific studies to address ambula-
tory blood pressure measurement in people with diabetes 
who are on dialysis.
While 24-h ambulatory blood pressure measurement 
(ABPM) is considered gold standard in predicting out-
comes, it is resource intensive, impractical in for long-
term monitoring of BP control and often not tolerated by 
individuals. Interdialytic home blood pressure (HBPM) 
is close to ABPM in predicting outcomes, but has high 
attrition rate for long-term monitoring. As routinely 
collected peri-dialytic BP measurements guide interven-
tions in the majority of dialysis units, it is essential to 
ensure routinely collected dialysis unit BP readings are 
measured in a standardised manner in accordance with 
recommended guidelines.
Target blood pressure in people with diabetes who are 
on dialysis
The relationship between blood pressure level and car-
diovascular outcome is unclear in individuals who are on 
dialysis. Observational studies have shown an increased 
risk of mortality in people who are on haemodialysis 
who have a low pre- or post-dialysis systolic blood pres-
sure of < 110 mmHg [254], and in those who are on peri-
toneal dialysis with a pre-dialysis systolic blood pressure 
of < 110 mmHg [255]. Further observational studies in 
haemodialysis cohorts [256, 257] continued to show a 
reverse epidemiology phenomenon, with the highest 
mortality rate being in groups with lower pre-dialysis 
blood pressures. Recent observational relationship stud-
ies using peri-dialytic measurements have consistently 
shown a ‘U’- or ‘J’-shaped relationship with mortality. 
For example, analysis of Dialysis Outcomes and Prac-
tice Patterns Study (DOPPS) data, at both facility and 
individual patient level, found lowest mortality in those 
with a pre-HD SBP of 130 to 159 mmHg (facility level) 
and < 130 mmHg (individual patient level); the facility-
level analysis compensates for unmeasured confounding, 
albeit in an imperfect manner [258]. Similarly, the CRIC 
Investigators reported a pre-HD SBP of 138 to 166 mmHg 
to be associated with lowest risk of cardiovascular events 
[259].
Interestingly, in the Tassin group in France where the 
5-year survival rate of 87% is the best reported in people 
who are on haemodialysis, the pre-dialysis blood pres-
sure that was achieved was < 130/85 mmHg (mean arte-
rial pressure (MAP) < 101 mmHg) [260].
Prospective randomised controlled studies on the effect 
of ARBs [261], ACEIs [262], beta blockers [263] and cal-
cium channel blockers [264] on cardiovascular events 
have been conducted to evaluate the roles of these agents 
in people who are on dialysis.
Two meta-analyses have shown that blood pressure 
treatment in people who are on dialysis is associated with 
improved outcome. The first analysis was by Heerspink 
et al, published in 2009 [265]. This meta-analysis included 
eight randomised trials that provided data from 1679 
people who are on dialysis, of whom 588 had diabetes. 
The trials included people who were on haemodialysis 
and peritoneal dialysis. The analysis showed that blood 
pressure lowering treatment was associated with lower 
risks of cardiovascular events, all causes of mortality and 
cardiovascular mortality, and that the effect seemed to 
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be consistent across a range of groups that were included 
in the studies. Reduction in systolic blood pressure was 
similar, regardless of whether the person had diabetes or 
antihypertensive drug use. Similarly, the second meta-
analysis by Agarwal and Sinha (also published in 2009) 
[266] showed that in people with hypertension who were 
on haemodialysis, antihypertensive therapy reduced 
the combined hazard ratio for cardiovascular events by 
31–38% compared with the placebo group. The meta-
analysis showed that blood pressure lowering was well 
tolerated, with no suggestion of increased adverse events 
in people with diabetes. The analysis showed no differ-
ence in cardiovascular outcomes caused by different drug 
classes and the data from the two meta-analyses suggest 
that RAAS blockers, beta blockers and calcium chan-
nel blockers are all suitable for use in people who are on 
dialysis.
However, a randomised controlled trial by Agarwal 
et  al in 2014 [267], including 200 people who were on 
haemodialysis of whom nearly half had diabetes, showed 
that a beta blocker-based hypertensive treatment was 
superior to an ACEI-based treatment in preventing car-
diovascular morbidity in those who are on dialysis.
Irrespective of the type of the antihypertensive agents 
that are used, the timing of the administration of such 
agents in relation to dialysis treatment needs to be taken 
into account when prescribing antihypertensive drugs 
for people who are on dialysis. ARBs, calcium channel 
blockers and alpha-blockers are not cleared with dialysis. 
However, ACEIs (apart from fosinopril) and a number of 
beta blockers are largely cleared on dialysis [268].
To date, optimum blood pressure goals for individuals 
who are on dialysis (including people with diabetes) have 
not been defined in randomised prospective controlled 
trials [268]. The Kidney Disease Outcomes Quality Initia-
tive (KDOQI) recommends a pre-dialysis blood pressure 
goal of < 140/90 mmHg and a post-dialysis blood pressure 
goal of < 130/80 mmHg [269]. However, this is largely 
based on studies that were performed in the non-dialy-
sis population who have normal renal function. People 
who are on haemodialysis have different characteris-
tics to the general population. For example, studies have 
shown that people who are on dialysis lose their diurnal 
blood pressure variation (that is, they are non-dippers), 
which is an independent risk factor for LVH and subse-
quent adverse cardiovascular outcome [247]. People who 
are on haemodialysis also have increased pulse pressure, 
which is associated with adverse cardiovascular outcome 
[270]. Therefore, the KDOQI-recommended blood pres-
sure target may not be applicable to the haemodialysis 
population.
Furthermore, people with diabetes who are on dialy-
sis are at increased risk of haemodynamic instabilities 
and orthostatic intolerance post-dialysis, and therefore 
a blood pressure that is higher than 140 mmHg systolic 
may be indicated in the presence of significant orthos-
tatic change in blood pressure. A randomised controlled 
trial is needed to identify the optimal blood pressure tar-
get for people with diabetes who are on dialysis.
As for those who are on peritoneal dialysis, Interna-
tional Society of Peritoneal Dialysis (ISPD) guidelines 
recommend a target of < 140/90 mmHg for self-measured 
home blood pressure readings [271]. However, this is 
based on a number of small observational studies and not 
specifically for those who have diabetes. There is no ran-
domised controlled trial evidence currently available.
Volume control in people with diabetes who are on dialysis
Increased extracellular volume or volume overload is an 
important contributor in the pathogenesis of high blood 
pressure in people who are on dialysis [272]. Removal 
of extracellular volume without causing intolerable 
Table 6 Recommendations for people with type 2 diabetes on dialysis
Recommendations for hypertension management and RAAS blockade in people with diabetes on modialysis
    1. We recommend that ambulatory blood pressure measurement or home blood pressure measurement should be used to monitor blood pressure 
in people with diabetes who are on dialysis (Grade 1C).
    2. Where ambulatory blood pressure measurement or home measurement are not feasible to monitor blood pressure in people with diabetes who 
are on dialysis, we suggest using pre‑, intra‑ and post‑dialysis standardised blood pressure measurements for people who are on haemodialysis, and 
using standardised clinic blood pressure measurements for people who are on peritoneal dialysis (Grade 2D).
    3. We recommend volume control as a first‑line management to optimise blood pressure control in people with diabetes who are on dialysis 
(Grade 1B).
    4. We suggest salt restriction to < 5 g per day to optimise blood pressure control in people with diabetes who are on dialysis (Grade 2C).
    5. We suggest a target upright interdialytic blood pressure of < 140/90 mmHg for people with diabetes who are on dialysis. Individualisation of the 
blood pressure target may be indicated in other people who are burdened with multiple comorbidities, in order to reduce adverse events of blood 
pressure lowering (Grade 2D). For peritoneal dialysis patients we also suggest the target BP is < 140/90 mmHg (Grade 2D)
    6. We recommend that intradialytic hypotension should be avoided in people with diabetes who are on haemodialysis (Grade 1B).
    7. We suggest using ACEIs or ARBs (but not in combination), beta blockers and calcium channel blockers to reduce cardiovascular complications in 
people with diabetes and hypertension who are on dialysis (Grade 2B).
    8. We suggest the use of diuretics in people with diabetes who are on dialysis and have residual renal function (Grade 2C).
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hypotension defines the ‘dry weight’ [273] that was first 
reported by Thomson in 1967 [274]. This is difficult to 
define clinically. Achieving dry weight and normalising 
blood pressure is not immediate and can take months, 
which is something that is best described as a ‘lag phe-
nomenon’ [275].
In the Tassin group, hypertension control without 
medication, achieved by aggressive control of extracellu-
lar volume and dietary sodium intake, was shown to be 
the best single marker of survival in 449 people who were 
on haemodialysis who were followed for 20 years [260].
Observational studies showed that volume control is 
associated with improvement in blood pressure in the 
majority of people on haemodialysis [276] and perito-
neal dialysis [277]. A randomised controlled trial (DRIP) 
showed that volume control in haemodialysis improves 
blood pressure control [278]. In that study, 150 peo-
ple were randomised to an additional ultrafiltration 
group (40/100 had diabetes) or control group (19/50 
had diabetes). Without increasing time or frequency 
of haemodialysis, reduction in dry weight (defined by 
clinical signs and symptoms) resulted in a reduction 
in interdialytic ambulatory blood pressure, leading to 
the conclusion that dry weight reduction is an effective 
strategy in blood pressure control in people who are on 
haemodialysis.
The concept that ‘volume control’ improves blood 
pressure control is further supported by the increas-
ing reports that daily dialysis [279, 280] or nocturnal 
dialysis [281, 282] improves blood pressure and reduces 
LVH with less risk of inducing intradialytic hypotension. 
Reducing the risk of intradialytic hypotension is impor-
tant. An observational study by Shoji T et al showed that 
haemodialysis-associated hypotension is an independent 
risk factor for 2-year mortality in people who are on hae-
modialysis [283].
The risk of intradialytic hypotension increases with 
an ultrafiltration rate of > 10 ml/kg/hr. and was reported 
in the Dialysis Outcomes and Practice Patterns Study 
(DOPPS) (which included 16,420 patients on haemodi-
alysis) as an independent risk factor for mortality [284]. 
This is similar to another study with 5 years’ follow-up 
data by Movilli [285], in which an ultrafiltration rate of 
over 12.7 ml/kg/hr. was identified as an independent risk 
factor for mortality given the risk of hypotension-related 
serious adverse events especially in people who are on 
dialysis and who have diabetes; however, this strategy 
requires close supervision and markers to assess volume 
status.
Bioimpedance spectroscopy devices [286], brain 
natriuretic peptide (BNP) level [287], assessment of vena 
cava diameter [288] and ultrasound lung water measure-
ment [289] have been used to determine dry weight. Of 
these, bioimpedance spectroscopy is most widely studied 
[290]. Further studies are needed to explore and evaluate 
the role of bioimpedance spectroscopy devices as mark-
ers of volume status, especially in people with diabetes 
who are on dialysis.
Salt restriction in people with diabetes who are on dialysis
Reducing dietary salt to control blood pressure in peo-
ple who are on dialysis was first reported by Hegstrom 
RM et al in 1961 [291]. Salt restriction to 1 g per day or 
less helps to decrease thirst and to control interdialytic 
weight gain in people who are on haemodialysis [292].
Evidence for the association between salt restriction 
and blood pressure control in people who are on dialy-
sis comes from observational studies where dietary salt 
restriction was in combination with strict volume con-
trol. Craswell et  al [293] (in a study of 89 people who 
were on dialysis), Covic et al [294] (in a study of 286 peo-
ple) and Ozkahya et  al [295] (in a study of 218 people) 
all showed that salt restriction to < 5 g per day along with 
strict volume control led to a significant reduction of 
blood pressure and interdialytic weight gain. Similarly, in 
the Tassin group, dietary salt reduction to < 5 g per day 
along with extracellular volume control was shown to 
normalise blood pressure in people who were on haemo-
dialysis [260].
In a cross-sectional study by Kayikcioglu et  al in 204 
people on dialysis, dietary salt restriction to 5 g per day 
along with dialysate sodium reduction, led to a reduction 
in interdialytic weight gain, the number of antihyperten-
sive medications and LVH [296]. Maduell and Navarro 
(in a cross-sectional study of 15 people) reported that 
salt restriction alone resulted in a significant reduction 
in interdialytic weight gain and blood pressure [297]. In 
the Haemodialysis (HEMO) Study, dietary sodium intake 
was associated with a greater adjusted risk of all-cause 
mortality [298]. In practical terms, adherence may be 
more sustainable if a threshold restriction of < 6 g dietary 
salt is applied in the diabetes cohort who have additional 
restrictions placed on them, but this has yet to be for-
mally evaluated.
Diuretic therapy may provide an additional means 
by which to promote natriuresis in people who are on 
dialysis who have residual urine output. In the DOPPS 
study, Bragg-Gresham et al reported that diuretic use 
was associated with reduced interdialytic weight gain, 
fewer intradialytic hypotensive episodes and reduced 
cardiac-specific mortality, but not all-cause mortal-
ity [284]. People with residual renal function who 
were on diuretics were twice as likely to retain resid-
ual renal function compared with those who were 
not on diuretics after 1 year in the study. The authors 
concluded that people with residual renal function 
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may benefit from continuing diuretic use rather than 
automatically discontinuing it at the start of dialysis. 
Furthermore, in a prospective randomised study by 
Medcalf et al on people who are on peritoneal dialysis, 
frusemide given at a dose of 250 mg once daily pro-
duced clinically significant preservation in urine vol-
ume over 1 year, but it had no influence on residual 
renal function [299].
Interestingly, and independent of its diuretic prop-
erty, spironolactone has been shown, in a randomised 
controlled trial that included participants with diabe-
tes, to be more effective than placebo in treating refrac-
tory hypertension in people on dialysis [300]. There 
is emerging evidence from a number of randomised 
controlled trials that spironolactone has a cardiac pro-
tective effect in people on dialysis [301], but it will 
be interesting to see what emanates from the current 
ongoing larger randomised controlled trial (ALdoster-
one Antagonist Chronic HEModialysis Interventional 
Survival Trial (ALCHEMIST)), which is exploring the 
potential cardiac protective role of spironolactone in 
people who are on dialysis [302]. It might help to show 
whether this effect is dependent or independent of 
spironolactone’s property as a diuretic and/or antihy-
pertensive agent.
To date there have been no randomised controlled tri-
als to address the question of whether salt restriction or 
diuretic use in people with diabetes who are on dialysis 
may influence blood pressure control or cardiovascu-
lar outcome. In the absence of such evidence, individu-
alisation of dietary sodium intake is required, depending 
on the person’s interdialytic weight gain, extracellular 
volume status, haemodynamic stability and nutritional 
status.
Research recommendations
There are areas which require further investigation 
including randomized controlled trials to further 
improve care of people with diabetes and CKD as high-
lighted in Table 7.
Table 7 The main research recommendations
The future research recommendations for type 1 and type 2 diabetes with different stages of CKD
The following areas lack good‑quality evidence for RAAS blockade and hypertension management in people with type 1 diabetes, and hence further 
research is necessary.
    1. In light of the fact that the presence of microalbuminuria in people with type 1 diabetes may not be the best predictor of whether they will 
develop progressive renal disease, what is the role for other markers (such as kidney injury molecule‑1 (KIM‑1)) in predicting the risk of renal disease in 
those with type 1 diabetes?
    2. What is the role of dual RAAS blockade in people with type 1 diabetes and nephropathy?
    3. What is the role of aldosterone receptor blockers in people with type 1 diabetes and nephropathy?
    4. Is there a role for home or ambulatory blood pressure monitoring in the diagnosis and management of hypertension in people with type 1 
diabetes, particularly in those who have diabetic autonomic neuropathy?
    5. Does measurement of plasma renin activity have a role in screening and managing hypertension in people with type 1 diabetes?
    6. Does tight glycaemic control and blood pressure lowering reduce the incidence of people developing microvascular complications in type 1 
diabetes?
    7. What is the role of RAAS‑blocking agents in people who have type 1 diabetes, progressive renal decline and normoalbuminuria?
    8. What is the impact on renal function of lower blood pressure targets in younger people with type 1 diabetes and nephropathy?
The following areas lack good‑quality evidence for RAAS blockade and hypertension management in people with type 2 diabetes, nephropathy and/
or early CKD, and hence further research is necessary.
    1. What is the best method for blood pressure measurement in people with type 2 diabetes who have CKD, particularly those with autonomic 
neuropathy?
    2. What is the evidence‑based lower limit for blood pressure reduction (< 130/80 mmHg) in people with type 2 diabetes who have CKD in terms of 
cardiovascular and renal endpoints?
    3. Can novel potassium binders enable a higher dosage of RAAS inhibitors or dual blockade with better attainment of blood pressure control and 
improvement in cardiovascular and renal outcomes?
    4. What are the best second‑ and third‑line blood pressure lowering agents in people with type 2 diabetes who have CKD and proteinuria?
    5. Is there a need for long‑term outcome studies of non‑dihydropyridine calcium channel blockers in diabetic nephropathy?
    6. Does bedtime hypertension treatment improve cardiovascular and renal outcomes in patients with type 2 diabetes and CKD?
    7. What is the role of lifestyle modifications (such as salt restriction, regular exercise, weight reduction) on blood pressure control, and cardiovascu‑
lar and renal outcomes?
The following areas lack good quality evidence and further research may help in people with diabetes on dialysis
    1. Which blood pressure measurement should be used to predict left ventricular hypertrophy (LVH) and mortality in people with diabetes who are 
on dialysis: pre‑dialysis, post‑dialysis, home or ambulatory blood pressure measurement?
    2. What is the optimal upright blood pressure target for people with diabetes who are on dialysis?
    3. Can bioimpedance spectroscopy devices be used to determine a target weight and predict the risk of cardiovascular morbidity for people with 
diabetes who are on dialysis?
    4. Does treatment with ACEIs, ARBs, beta blockers or calcium channel blockers to lower blood pressure in people with diabetes who are on dialysis 
reduce cardiovascular morbidity and mortality?
    5. Is there a role for diuretic therapy in people with diabetes who are on dialysis and have residual renal function?
    6. Does salt restriction (< 5 g per day) in people with diabetes who are on dialysis influence blood pressure control or cardiovascular outcome?
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Conclusion
People with diabetes and CKD have increased risk of 
morbidity and mortality. They experience excess cardio-
vascular events and progression of CKD. Hypertension is 
a common risk factor for both adverse outcomes. Tight 
control of blood pressure and the use RAAS inhibitors 
are associated with improved outcomes, particularly in 
the presence of proteinuria. RAAS inhibitors can cause 
side effects e.g. rising serum creatinine and hyperkalae-
mia. However, guideline-based therapy such as men-
tioned here can prolong life, lower risk of cardiovascular 
events and hospital admissions, and prevent end-stage 
kidney failure requiring renal replacement therapy.
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